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INTRODUCTION (1-12) 
 
 The analytical method is a generic process combining the power of the 
scientific method with the use of formol process to solve any type of research 
problem. It involves the steps like identify the problem to solve, choose an 
appropriate process, use the process to hypothesize analysis or solution elements, 
design an experiment to test the hypothesis perform the experiments to accept, 
reject or modify the hypothesis, check the performance before steps until the 
hypothesis is accepted, implement the solution continuously to improve process as 
opportunities arise. 
 The need of new analytical methods is vital in new drug development 
pharmaceutical products formulated with one or more than one drug was referred 
to be combination drug products, which are intended to meet previously unmet 
patient needs by combining the therapeutic effects of two or more drugs in one 
product. These combination products can produce daunting challenges to the 
analytical chemist responsible for the validation of analytical methods. 
 As a result of new drug research, number of drugs introduced into the 
market is increasing every year. These drugs may be either new entities or partial 
structural modification of the existing one. Often there is a time lag from the date 
of introduction of a drug into the market to the date of its inclusion in 
pharmacopoeias because of the possible uncertainties in the continuous and wider 
usage of these drugs, reports of new toxicities, development of patient resistance 
and introduction of better drugs to competitors, under these conditions, standards 
and analytical procedures for these drugs may not be available in the 
pharmacopoeias. It becomes necessary to develop newer analytical method for 
drugs. 
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 The information obtained from analytical research is used to identify 
potential sources of safety problems in the products. The analytical effort required 
to provide this information can be divided into a number of analytical tasks which 
are as below, 
 Determination of identify, purity of starting materials and intermediates 
 used in manufacturing the drug substance. 
 Isolation and identification of trace impurities in drug substance. 
 Determination of degradation rates and products. 
 Establishment of an analytical reference standard for the drug substance. 
The analytical methods require the meet crieterian like sensitivity, 
specificity, precise, robust and raggedness. The degrees of complexity acceptable 
in the analytical procedure vary considerably from task to task and therefore 
require a variety of analytical techniques to satisfy them. 
 
Basic criteria for new method development of drug analysis: 
 Drug or drug combination may not be official in pharmacopoeia. 
 A proper analytical procedure for the drug may not be available in the 
 literature. 
 Analytical methods for the quantitation of the drug may not be available. 
 Analytical methods for a drug in combination with other drugs only 
 available. 
 The existing analytical procedures may require expensive reagents and 
 solvents. 
Analysis of drugs by UV – Visible spectrophotometry 
 Analytical samples absorption in the UV-Visible region is often strong and 
therefore allows many substances to be measured in the low part per million 
ranges in non-absorbing media. Good sensitivity combined with ready availability 
of simple, accurate and inexpensive spectrophotometers have made UV- Visible 
spectrophotometry one of the most widely used instrumental techniques in organic 
analysis. 
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 There are various spectrophotometric methods are available which can be 
used for the analysis of a samples. 
 Simultaneous equation method 
 Derivative spectrophotometric method 
 Absorbance ratio method  
 Difference spectrophotometry 
Chromatography 
 Chromatography is the most powerful and versatile technique available to 
the modern analyst. A chromatographic procedure can separate a mixture of 
components into individual components and quantitatively determine the amount 
of each component present. 
 Development of chromatography has been quite remarkable in many ways. 
On one side the development of liquid chromatography was vens slow and 
arduous, particularly in the early years, whereas in comparison, the rate of 
development of gas chromatography was almost meteoric. HPTLC method for 
analyzing drug in single or multicomponent dosage forms required only primary 
knowledge, about the nature of sample namely, structure, polarity, volatility, 
stability and solubility parameters. An exact recipe for HPTLC, however also 
same like HPLC cannot be provided because method development involves 
considerable error and trial procedures.  
 The availability of disposable TLC plates, the problem caused by samples 
with high matrix contents, which block the HPLC columns and likely to give 
ghost peaks is eliminated by HPTLC system is automated and controlled 
throughout by software and is fully responsible and standardized cGMP - 
compliant technique. 
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It generates comparable analytical data with low level of uncertainly and is 
suitable for in process control for product analysis in simultaneous long-term 
comparison as batch-to-batch conformity for stability testing. 
Stability indicating analysis method is employed for the analysis of sample 
stability in pharmaceutical industry. ICH guidelines explicity requires conduct of 
forced decomposition studies under a variety of conditions like pH, light, 
oxidation, dry heat and separation of drug from degradation products. Drugs 
containing functional groups such amides, esters, lactams, lactones easily undergo 
hydrolysis. Drug containing functional groups such as thiols, thioesters, easily 
undergo oxidation. Drug containing functional groups such as olefins, aryl halo 
derivatives, aryl acetic acids, aromatic nitro groups, N- oxide easily undergoes 
photo decomposition. This was the first step carried out in a drug structure to 
assess the likely decomposition route; secondly, collection of information on 
physicochemical properties was done which may be an easy exercise when the 
degradation products are known and available in the pure form. 
HPLC systems can be modular basis in which the users can use different 
modules (e.g. Column and detector) depending on the analytical requirements. All 
basic compounds are difficult to be separated or purified on silica based reversed 
phase material for liquid chromatography because undesired adsorption of the 
basic nitrogen containing group to acidic sites on the silica surface. 
The HPLC method developments focus specifically a suitable approach for 
isocratic reversed phase method development, since this is most commonly used 
in pharmaceutical field. 
 
 Samples description includes the number of compounds: chemical 
structure/function, molecular weight, pKa, UV spectra, matrix, solubility 
and analyte concentration. 
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 Specification of goals includes analysis, purification or preparation? 
Qualitative and quantative analysis? Resolve all compounds and what is 
precision needed? 
 Pretreatment of sample includes ready to inject or clean up needed? For 
 example, dilution, buffering or solubility. 
 Selection of detector where UV is the most desirable detector. 
 The order of selection of method is, 
1st choices: RPLC, ION PAIR OR NPLC 
2st choices: IEC, SEC, HIC 
 
Special cases: high molecular weight, isomers, inorganic, carbohydrates 
 Initial runs can be isocratic and gradient. 
 Optimization of resolution includes how much resolution needed? Time 
per run? Operating pressure? Solvent consumption and narrow peaks? 
 Validate before the release of method which meets all goals, robust, 
 routine method. 
Validation as such cannot improve the process but it confirms and assures 
that the process has been well maintained and operates as it should validation is a 
basic requirement to ensure quality and reliability of the results for all analytical 
applications. It is essential to employ well characterized and fully validated 
analytical methods to yield reliable and recognized results in the laboratories 
while analyzing the registration batch and accelerated stability testing samples. It 
is also essential to emphasize that each analytical technique has its own 
characteristics, which will vary from analyte to analyte. The importance of 
validation is producing reliable, repeatable and accurate results for routine 
analysis and stability analysis studies carried out during the entire period of work. 
Validation of analytical procedures is directed to the four most common types of 
analytical procedures such as identification tests, quantitative test for impurity 
content, limit test for control of impurities and quantitative test for the active 
moiety in samples of drug substance or drug product. 
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Key parameters of the analytical method validation includes, precision 
(repeatability and reproducibility), linearity and range, limit of detection (LOD), 
limit of quantification (LOQ), selectivity/specificity, robustness, stability system 
suitability studies. 
Statistics is a wide tool useful in all disciplines especially in research 
studies. One should know about the importance of statistical tools and how to use 
them in their research o survey. The quality assurance of the work must be dealt 
with the statistical operations to control and verify the analytical procedures as 
well as the resulting data making mistakes in analytical work is unavoidable. This 
is the reason why a multitude of different statistical tools is required some of them 
simple, some complicated and often very specific for certain purposes. In analytic 
work, the most important common operation is the comparison of data or sets of 
data, to quantity of accuracy and precision. Fortunately with a few simple 
convenient statistical tools most of the information needed in regular laboratory 
work can be obtained in t-test, F-test, ANOVA test and regression analysis. 
Clearly statistics are a tool not an aim. The value of statistics lies with organizing 
and simplifying data to permit some objective estimate showing that an analysis is 
under control or that a change has occurred. 
  
Review of Literature 
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REVIEW OF LITERATURE (13-18) 
 The need of survey of literature is to see what has and has not been 
investigated and identify data sources that other researchers have used. To learn 
how others have defined and measured key concepts and develop alternative 
research projects. Review of literature helps to demonstrate understanding and 
ability to critically evaluate research in the field and to provide evidence that may 
be used to support one’s own findings. 
 A review of literature was conducted for the analysis of Benfotiamine, and 
its combination with Pyridoxamine dihydrochloride and Resveratrol are described 
below, 
Siva sankari K.A (2016) et al., have developed and validated UV 
spectroscopic method for the estimation of Benfotiamine in bulk and solid dosage 
form. The simple, precision, accurate, UV spectrophotometric methods namely 
dual wavelength spectrophotometric method and difference UV 
spectrophotometric method have been developed using 0.1 N HCL as solvent. The 
HCL drug obeyed Beer’s law in range of 5-25µg/ml. The overall percentage 
recovery found to be 99-100%. 
 B. Pavan aditya (2016) et al., have developed a new simple, precision, 
sensitive and validated RP-HPLC method for the estimation of Benfotiamine in 
bulk and pharmaceutical dosage form. The chromatographic conditions used for 
the separation was phenomenox Luna C18 (4.6×250mm.5µ) and mobile phase 
comprised of acetonitrile: methanol: water: 0.1% OPA (40: 20: 35:5 v/v). The 
flow rate was 1.0ml with detection at 249nm. The retention time was found to be 
3.84 min. The linearity was found to be in the range of 5-35µg/ml for 
benfotiamine with correlation coefficient of 0.999. The method was successfully 
applied to pharmaceutical formulation. 
Review of Literature 
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 Deepali A. Nanaware (2011) et al., have developed a simple, sensitive 
and rapid RP-HPLC method for the estimation of Benfotiamine and Metformin 
hydrochloride in pure and in pharmaceutical dosage forms. Thermo hypersil BDS- 
C18 column (250mm×4.6mm, 5µ Germany) with isocratic conditions was used 
with mobile phase containing mixture of methanol and aqueous phosphate buffer 
(10mM of potassium phosphate adjusted with 3.2 with OPA) in the ratio of 80: 20. 
The flow rate was 1ml/min and effluents were monitored at 239nm and eluted at 
2,583 min (BEN) and 3.233 min (MET). Calibration curve was plotted with range 
of 1-6µg/ml for BEN and 0.1-5µg/ml. 
 S. Poongothai (2014) et al., have developed a simple, precise, rapid and 
validated selective RP-HPLC method for the simultaneous determination of 
Benfotiamine (B1) 100mg, Pyridoxine hydrochloride (B6) 100mg Mecolamine 
(B12)100mcg and Alpha-lipoic acid 100mg in Multivitamin capsules. The method 
was x- tetra reverse phase (RP-18, 250×4.6mm, 5µm) column and gradient 
elution. The aqueous mobile phase contained 0.05M phosphate buffer adjusted pH 
2.5 and acetonitrile. Separation and quantification was achieved by changing the 
proportion of the system linearity. Detection was carried out in the range of 200 to 
600nm using photodiode array detector set at 320 nm and further analysis was 
carried out using UV detector. 
 Marsza. M (2013) et al., have developed a rapid and sensitive HPLC 
method with coulometric electrochemical and UV detection for analysis of 
vitamin (B1) Thiamine, (B6) Pyridoxamine, Pyridoxal and Pyridoxine and (B12) 
in Animal and Plant foods has been developed. A combination of acid digestion 
and enzymatic extraction of release protein bound and a phosphorylated vitamin 
followed by HPLC analysis was applied. The analysis were carried out on a LC 18 
column 5µ (250cm×4.6mm) using the mobile phase consisting of methanol: 
phosphate buffer (10:90) and 0.018M Triethylamine, adjusted pH 3.5  
following 1.0ml/min. The method offer excellent linearity with regression 
coefficient r > 0.998. 
Review of Literature 
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Roopa.S. Pai (2013) et al., have developed a new formulation of t-Rvt 
loaded PLGA nanoparticle with potential stearth properties was prepared by nano 
precipitation method in our laboratory. The desired chromatographic separation 
was achieved on a phenomenox C18 column under isocratic conditions using UV 
detection as 306nm. The optimized mobile phase consisted of a mixture of 
methanol: 10mM potassium dihydrogen phosphate (pH 6.8): Acetonitrile  
(63:30:7 v/v/v) at a flow rate of 1.0ml/min. The linear regression analysis for the 
calibration curves showed a good linear correlation over the concentration range 
0.025-2.0µg/ml with determination co-efficient exceeding 0.9997. 
Aim & Objective 
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AIM AND OBJECTIVE 
 Benfotiamine is an antioxidant dietary supplement drug used in diabetic 
neuropathy. The US FDA approved benfotiamine in January 18, 2006 to diabetic 
neuropathy and benfotiamine in combination of pyridoxamine dihydrochloride 
and resveratrol. 
Literature reveals very few analytical techniques for the estimation of 
benfotiamine from tablets. Also there is no analytical method reported for the 
combination of benfotiamine with pyridoxamine dihydrochloride and resveratrol, 
till date.  
Hence the major objective of the present research work is, 
 To develop and validate UV spectroscopic method for the estimation of 
 benfotiamine in bulk drug and tablet formulation. 
 
 To develop and validate stability indicating HPTLC method for the 
determination of benfotiamine and its application of accelerated stability 
studies of benfotiamine tablets. 
 
 To develop and validate a HPTLC method for estimation of benfotiamine 
in combination with pyridoxamine dihydrochloride and resveratrol in 
combined dosage from. 
 
 To develop a validated RP-HPLC method for estimation of benfotiamine 
in combination with pyridoxamine dihydrochloride and resveratrol tablet 
formulation. 
 
Drug Profile 
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DRUG PROFILE(13,14,16,18) 
 
Name                                      : Benfotiamine  
IUPAC Name                        : S-[2-{[(4-amino-2-methylpyrimidin-5-yl) methyl] 
                                                 (Formyl) amino}-5-(phosphonooxy) pent-2-en-3yl] 
                                                 Benzenecarbothioate. 
Empirical Formula               : C19H23N4O6PS. 
Structure Formula                :   
 
Molecular Weight          :  466.448 g/mol. 
Description                     : White to off white powder. 
Solubility                        : water, aqueous solvents.  
Melting point                 : 165ºC 
Bioavailability                :  33.8% 
Storage                           :  Stored in tightly closed container in a drug &  
  ventilated place.                                               
Category                         :  Vitamin B1                                                                         
Action and use                :  Vitamin B1 analog. Synthetic S-acyl derivative of  
                                                Thiamine, antioxidant, advanced glycation end  
                                                Product supplement, treating diabetic complications. 
Available dosage forms:  Tablets, Capsule. 
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Name                              :  Pyridoxamine Dihydrochloride.  
 
IUPAC Name                  : 4-(amino methyl)-5-hydroxy-6-methyl-3-pyridine 
                                                 Methanol dihydrochloride. 
Empirical Formula         : C8H14CI2N2O2 
Structural Formula        :  
 
Molecular Weight           : 241.11 g/mol. 
Description                       :  Yellow to green powder. 
Solubility                          : Water, DMSO, Methanol, Ethanol, Acetone. 
Melting point                   : 226- 227ºC 
Bioavailability              :  65% 
Storage                             :  Stored in tightly closed container in a drug & 
ventilated place.                                                    
Category    : Vitamin B6. 
Action and use : An inhibitor of advanced glycation reactions, also  
                                                Inhibits advanced lip oxidation reactions. 
                                                Dietary supplement and prevent the progression of  
                                                Diabetic nephropathy. 
Available dosage forms   : Tablet. 
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Name                                : Resveratrol  
IUPAC Name     :  3, 5, 4’-trihydroxy-Trans –stilbene. 
Empirical Formula         : C14H12O3 
Structural Formula         : 
 
Molecular Weight            : 228.25g/mol. 
Descriptions                     : White powder with slight yellow cast. 
Solubility                          : Water, DMSO, Ethanol, Methanol, Acetone. 
Melting point                   : 261-263ºC 
Bioavailability                 : 70% 
Storage                            : Stored in a dry and cleaned place. 
Category              : Antioxidant. 
Action and use    : NF-Kb inhibitory action of resveratrol a probable  
                                                Mechanism of neuroprotection in  
                                                Diabetic neuropathy revolves around oxidative  
                                                Stress, AGE formation, lipid peroxidation. 
Available dosage form    : Tablet. 
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Benfotiamine is available as single and in combination with pyridoxamine 
dihydrochloride & resveratrol as shown in below, 
BRANDS AVAILABLE  
Brand Name            Composition  Company 
BENALGIS tab Benfotiamine 75mg/100mg FRANCO 
FOTIA tab Benfotiamine 150mg BESTOCHEM 
BENFAGE tab Benfotiamine 100mg/200mg ORCHID 
BENFORCE tab Benfotiamine 150mg SHIELD 
VITAMER-EA cap Benfotiamine 50mg CARSYON 
AGELESS tab 
Benfotiamine 50mg, 
pyridoxamine dihydrochloride 
25mg, resveratrol 25mg 
APEX 
ASIA tab 
Benfotiamine 50mg, 
pyridoxamine dihydrochloride 
25mg, resveratrol 25mg 
APEX 
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MATERIALS AND INSTRUMENTS 
CHEMICALS AND SOLVENTS USED 
 Water for HPLC  
 Methanol HPLC grade (99.8%) 
 Methanol AR grade (99.0%) 
 Acetonitrile HPLC grade (99.9%) 
 Triethylamine AR grade (99.0%) 
 Petroleum ether AR grade (99.0%) 
 Acetone AR grade (99.5%) 
 Tetra butyl ammonium bromide  
 Potassium dihydrogen orthophosphate 
 Glacial acetic acid (99.0%) 
 Orthophosphoric acid  
 Distilled water 
 All the above chemicals and solvents were supplied by S.D fine chemicals 
Ltd, India, qualigens fine chemicals Ltd, Mumbai, India, sigma – Aldrich 
chemicals Pvt. Ltd., Maharashtra, India.  
MATERIALS USED 
 Pre- coated silica gel 60F254 on aluminum sheets were procured from 
 Merck, Germany. 
 Cellulose filters 0.45µm. 
 Poly tetra fluoro ethylene filter 0.45µm, dimension 47mm. 
 LICHRO. SPHER ®100 RP-18e (5µ), (250×4.6MM column). 
 Whattmann filter paper 
 
Materials & Instruments 
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INSTRUMENTS  
 Shimadzu digital electronic balance 
 Elico Pvt, Limited, india, pH meter. 
 Camag HPTLC system (with TLC scanner-3) wins CATS software and 
 Linomat 5 as application device. 
 Shimadzu HPLC system with SPD-M10 A VP system PDA with 20µl 
fixed volume manual injector and LC-MS solution software. 
 Jasco V-630 spectrophotometer with a pair of 1 cm quartz cuvette. 
 Sonicator (leelasonic ultrasonic Sonicator)   
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I. DEVELOPMENT AND VALIDATION OF UV 
SPECTROSCOPIC METHOD FOR THE ESTIMATION 
OF BENFOTIAMINE IN BULK DRUG AND TABLET 
FORMULATION 
    
 Benfotiamine is having chromosphores in its structure and hence it will 
absorb electromagnetic radiation between 200-400nm. This character is used for 
estimating Benfotiamine by UV spectroscopic method. 
 
OPTIMIZATION OF EXPERIMENTAL CONDITION: 
Selection of solvent: 
The solubility of drug was checked in different solvents and found to be 
completely soluble in methanol. A UV spectrum of drug solution in methanol was 
recorded. Smooth spectrum with reasonable absorbance was obtained and hence it 
was selected as solvent for further studies. 
 
Preparation of stock solution: 
Stock solution Benfotiamine (1000µg/ml) was prepared LR grade 99% 
methanol in 10ml glass volumetric flask. 
 
Selection of wavelength: 
The working standard solutions were scanned in UV range of (200-400nm) 
using a Jasco V-630 UV-Visible spectrophotometer with cells of 10mm length 
against the same solvent used as blank. It was scanned in the range of 200-400 nm 
and it shows absorbance maxima at a maximum wavelength of 240nm.  
 
  
Experimental Section 
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VALIDATION OF THE METHOD 
The developed method was validated as per ICH guidelines (19) in terms 
linearity, accuracy, precision, repeatability, LOD, LOQ and robustness. 
 
Linearity and range: 
Various aliquots were prepared from the secondary stock solution 
(100µg/ml) concentration ranging from 4-24µg/ml. The samples were scanned in 
UV-Visible spectrophotometer against methanol as blank. At 240nm the 
absorbance of standards were measured. The calibration graph was plotted against 
concentration versus absorbance. The slope, intercept and correlation coefficient 
values were calculated. 
 
Accuracy: 
Solutions were prepared in at levels 50% and 100% of test concentration 
using Benfotiamine working standard as per the test method and taken absorbance 
of each solution in triplicate. The Recovery results showed that the proposed 
method has an acceptable level of accuracy.  
 
Precision: 
   Precision of the method was demonstrated by intra-day, inter-day and 
repeatability variation studies. 
 Precision of the method was studied by 
 Intra-day precision  
 Inter-day precision  
 Repeatability  
 
Intra-day precision: 
      In intra-day variation study nine different solutions of same concentration 
12µg/ml and 16µg/ml were analyzed three times in a day i.e. morning, afternoon, 
and evening and the absorbance is noted and from the mean, standard deviation 
and RSD% were calculated.  
Experimental Section 
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Inter-day precision: 
In inter-day variation studies, solution of same concentration 12µg/ml and 
16µg/ml were analyzed three times for the consecutive days and the absorbance 
result mean, standard deviation and RSD% was calculated. 
 
Repeatability: 
        The repeatability was studied by carrying out the analysis of the standard 
drug concentration 12µg/ml in the linearity range of the drug for six times on the 
same day and the response for each concentration was recorded and %RSD was 
calculated. 
 
 
Limit of detection (LOD) and limit of quantification (LOQ): 
       The lowest concentration detected (LOD) and lowest concentration 
quantified (LOQ) were estimated from the set of five calibration curves used to 
determine method linearity. 
                         LOD = 3.3×σ/S and LOQ = 10×σ/S 
Where, σ = the standard deviation of y intercepts of regression lines 
             S = the slope of the calibration curve 
 
Solution stability: 
      The stock solution of Benfotiamine was stored at room temperature and under 
refrigeration. The absorbance of solution was measured at different time interval. 
The % reductions in absorbance were noted to calculate stability of solution. 
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Analysis of formulation: 
Benalgis (100mg) was assayed by developed UV spectrophotometric 
method. Twenty tablets were weighed and finely pulverized and the quantity of 
homogenized powder equivalent to 10mg of Benfotiamine was transferred to 10ml 
volumetric flask. It was dissolved by adding small volume of methanol and 
sonicated for five minutes. The volume was made up with the same solvent. The 
solution was filtered using whattmann filter paper. Suitable dilution was made and 
the corresponding UV spectrum of formulation solution was recorded. The 
absorbance was noted at 240nm and the amount per tablet and % label claim were 
calculated.  
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II.  DEVELOPMENT AND VALIDATION OF STABILITY 
INDICATING HPTLC METHOD FOR THE 
DETERMINATION OF BENFOTIAMINE AND ITS 
APPLICATION TO ACCELERATED STABILITY 
STUDIES OF BENFOTIAMINE TABLETS  
The present work is to develop an economic accurate, reproducible and 
stability indicating HPTLC method for the determination of benfotiamine in the 
presence of its degradation products and related impurities from pharmaceutical 
formulation.  
Selection of plate 
         A pre-coated silica gel G60 F254 coated on aluminum sheet was selected for 
the study. 
Selection of solvent 
          Drug should be soluble in the solvent used. 
          Drug should show stability in the solvent used. 
          Solvent should be volatile. 
          Ideal properties of a solvent employed for HPTLC are, 
          Methanol was selected as the solvent here for further studies as the 
benfotiamine was soluble and fulfilling above criteria. 
           
Selection of wavelength  
         The sensitivity of HPTLC method depends upon the proper selection of 
wavelength for UV detection. An ideal wavelength is the one that gives maximum 
absorbance and good response for the drug at the lower concentration is to be 
selected. The UV spectrum of Benfotiamine was recorded in HPTLC scanner and 
maximum wavelength was found to be 275nm. This wavelength selected  
for the study. 
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Detection of optimum mobile phase  
         A mobile phase system that would give dense compact spots and good 
separation from solvent and application position was to be selected. Initially, 
different solvent systems were tried and there observations were as given below: 
Table 1: Selection of Mobile Phase 
Solvent system tried Observation 
100% Methanol Drug move but spot not clear. 
100% Acetic acid Drug move but spot not clear. 
Acetic acid: Methanol(1:9v/v) Drug retained. tailed spot 
Acetic acid: Methanol(2:8v/v) Drug retained, tailed spot 
Acetic acid: Methanol: Tetra butyl 
ammonium bromide(9:1v/v:2 drops) Drug retained, tailed spot 
Acetic acid: Methanol: 
Triethylamine(8:2v/v: 2drops) Drug retained, tailed spot 
Acetic acid: Methanol: 
Triethylamine(9:1v/v: 2drops) Good separation with compact spot. 
 
Chromatographic development procedure: 
        Suitable volume of standard solution was spotted in the form of bands 
having a band width of 6mm on precoated silica gel G60 F254 HPTLC plate, 8mm 
from the bottom and 15mm from the side edges in the form of bands. Linear 
ascending development was carried out and the optimized mobile phase consisted 
of glacial acetic acid: methanol: Triethylamine (9:1v/v: 2 drops). The optimized 
chamber saturation time before chromatographic development was  
15 min and the length of chromatographic run was 8cm. Subsequent to the 
development, HPTLC plates were dried in a current of air with help of an air 
dryer. Densitometric scanning was performed and all measurements were made in 
the reflectance absorbance mode at 275nm, with slit dimension (5.00 × 0.Ͷͷmm) 
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the source of radiation was deuterium lamp emitting a continuous UV spectrum 
between 200-400nm. Concentrations of the compound chromatographed were 
determined from the intensity of diffusely reflected light and evaluation was done 
by ordinary linear regression analysis. 
Optimization of chamber saturation  
The above fixed mobile phase was added to one side of twin trough 
chamber previously rinsed with acetone and dried then saturation times fixed as 
15 minutes. 
Fixed Experimental Conditions 
Stationary phase  : Pre-coated silica gel G60F254 on aluminum sheets 
 Mobile phase                     : Glacial acetic acid: Methanol: Triethylamine 
 Chamber saturation time    : 15 min 
 Plate migration distance     : 80mm 
 Band width                          : 6mm 
 Slit dimension                     : 5 × 0.45mm 
 Source of radiation              : Deuterium lamp 
 RF value                               : 0.29±0.02 
 Detection wavelength          :  275nm 
Preparation of stock solutions 
10mg of Benfotiamine were taken into a 10ml standard flask and made up 
to the volume with methanol to get a stock solution of 1000µg/ml. 
Experimental Section 
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VALIDATION OF THE METHOD: 
The developed method was validated as per ICH guidelines. The validated 
method was carried out in terms of linearity, accuracy, precision, repeatability, 
LOD and LOQ. 
Linearity and range: 
A solution containing 1000µg/ml of Benfotiamine was prepared in 
methanol. Different volumes from 0.2 – 1.2µl of this solution were applied on the 
plate. After development the plate was scanned and peak area were noted. Linear 
regression data showed good correlation coefficient over a concentration range of 
200-1200ng/spot. 
Accuracy: 
Recovery study was in order to ensure the suitability and reliability of 
HPTLC method, recovery studies were carried out. It was done by mixing known 
quantities of the standard drug (50 & 100% level) with the analyzed sample 
formulation and the contents were reanalyzed by proposed method. 
Precision: 
    Precision of the method was studied by 
 Intra-day precision  
 Inter-day precision  
 Repeatability precision 
Repeatability of sample measurement 
Repeatability of sample application 
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Intra-day precision: 
Intra-day precision was studied by carrying out the analysis of the standard 
drug for two different concentrations for three times on the same day and %RSD 
was calculated. 
Inter-day precision: 
Inter-day precision was studied by carrying out the analysis of the standard 
drug for two different concentrations for three different days over a period of one 
week and %RSD was calculated. 
Repeatability: 
Repeatability of sample measurement: 
       Repeatability of measurement was determined by spotting 600ng/spot of 
drug solution on a pre-coated TLC plate and developed the plate and scanned six 
times %RSD was calculated. 
Repeatability of sample application: 
      Repeatability of sample application was carried by spotting 4µl of drug 
solution is about six times on pre-coated TLC plate followed by development of 
plate and %RSD was calculated. 
Limit of detection (LOD) and limit of quantification (LOQ): 
       The lowest concentration detected (LOD) and lowest concentration 
quantified (LOQ) were estimated from the set of five calibration curves used to 
determine method linearity. 
                         LOD = 3.3×σ/S and LOQ = 10×σ/S 
Where, σ = the standard deviation of y intercepts of regression lines 
 S = the slope of the calibration curve 
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Robustness: 
   The robustness of the method is its ability to remain unaffected by small 
changes in practical conditions. Here the effect of change in conditions such as 
ratio of mobile phase (±0.1ml) and (±0.2min) were studied to prove robustness. 
Specificity: 
The peak purity of Benfotiamine was assessed by comparing its respective 
spectra at peak start, peak apex and peak end positions of the spot. 
Stability studies: 
When the developed chromatographic plate is exposed to atmosphere, the 
analytes are likely to be decomposed. It is necessary to study the stability of drug 
on TLC plate. It was studied by scanning the plate at different time interval and 
peak areas were compared with the peak area of freshly scanned plate. The 
developed TLC plate was found to be stable for about 12 hours for Benfotiamine. 
ANALYSIS OF TABLET FORMULATION 
To determine the amount of Benfotiamine in various tablet dosage forms 
(label claim 100mg per tablet), the contents of 20 tablets were weighed, their 
mean weight was determined, and they are finely powdered. An accurately 
weighed powder sample equivalent to 10mg of Benfotiamine was transferred into 
a 100ml volumetric flask containing 10ml methanol, followed by sonication for 
10min. The resulting solution was filtered through whattmann filter. A volume of 
0.6µl of the filtered solution (600ng/band) was applied on the HPTLC plate 
followed by development and scanning as per optimized chromatographic 
conditions. 
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Application of HPTLC method to Accelerated stability study of benfotiamine   
Forced degradation studies: 
To evaluate the stability indicating property of the developed HPTLC 
method, standard drug was subjected to acid/base hydrolysis, and oxidation. 
100mg of pure drug Benfotiamine was accurately weighed and transferred to 
100ml volumetric flask and diluted with methanol to obtain a final concentration 
of 1000µg/ml. The solution was further subjected to following forced degradation 
study.  
Acid- induced degradation study:  
To 15ml of the above methanolic standard drug solution 10ml of 1N, 0.1N, 
and 0.01N hydrochloric acid was added in three different 25ml volumetric flask 
and this solution was refluxed at 40ºC for 5 hrs.  Neutralized solution was directly 
applied to HPTLC plate followed by development and scanning under optimized 
chromatographic conditions. 
Base – induced degradation study: 
To 15ml of the above methanolic standard drug solution 10ml of 1N, 0.1N, 
and 0.01N sodium hydroxide was added in three different 25ml volumetric flask 
and this solution was refluxed at 40ºC for 5 hrs.  Neutralized solution was directly 
applied to HPTLC plate followed by development and scanning under optimized 
chromatographic conditions. 
Hydrogen peroxide – induced degradation study: 
To 15ml of the above methanolic standard drug solution 10ml of 30% 
hydrogen peroxide solution was added in 25ml volumetric flask and this solution 
was refluxed at 40ºC for 5 hrs.  Neutralized solution was directly applied to 
HPTLC plate followed by development and scanning under optimized 
chromatographic conditions. 
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   Degradation of placebo of formulation: 
 A placebo (or dummy pill) (20) is an inert substance, typically a tablet, 
capsule, or other dose form that does not contain an active drug ingredient. For 
example, placebo pills or liquids may contain starch, sugar, or saline. 
   The fixed chromatographic condition was applied to estimate placebo 
ingredients. The placebo was subjected for acid/base hydrolysis and oxidation as 
per the procedure monitored in degradation study. The placebo was prepared 
using excipients as below. 
Excipients Weight taken 
Lactose 0.45g 
Calcium carbonate 0.25g 
Magnesium stearate 0.01g 
Gelatin 0.24g 
Poly vinyl pyrrolidine 0.05g 
  The placebo mixture was weighed dissolved and  subjected to various 
stress conditions a volume of 0.6µl was spotted on TLC plate in triplicate 
analyzed using fixed chromatographic conditions described earlier. 
Degradation of Benfotiamine in formulation: 
The fixed chromatographic condition was applied to estimate 
Benfotiamine from tablets. The Benfotiamine tablet was subjected for acid 
hydrolysis, base hydrolysis, oxidative degradation, thermal degradation and 
photolytic degradation same as that bulk drug. 
From the various stress samples prepared 0.6µl was spotted on TLC plate 
in triplicates analyzed using fixed chromatographic conditions described earlier. 
The chromatograms were obtained for any addition peak and change in 
benfotiamine peak. 
Experimental Method 
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III. DEVELOPMENT AND VALIDATION OF HPTLC 
METHOD FOR ESTIMATION OF BENFOTIAMINE  
IN COMBINATION WITH PYRIDOXAMINE 
DIHYDROCHLORIDE AND RESVERATROL IN 
COMBINED DOSAGE FORM. 
 
The experimental work consists of optimization of chromatographic 
conditions development and validation of HPTLC method of Benfotiamine in 
combination of Pyridoxamine dihydrochloride and Resveratrol. 
Selection of plate 
         A pre-coated silica gel G60 F254 coated on aluminum sheet was selected for 
the study. 
Selection of solvent 
          Drug should be soluble in the solvent used. 
          Drug should show stability in the solvent used. 
          Solvent should be volatile. 
          Ideal properties of a solvent employed for HPTLC are, 
          Methanol was selected as the solvent of sample for further studies, as the 
drug was soluble and fulfilling above criteria. 
Selection of wavelength  
         The sensitivity of HPTLC method depends upon the proper selection of 
wavelength for UV detection. An ideal wavelength is that the overlay that give 
maximum absorbance and good response for the drug to be selected at the lower 
concentration is to be selected. The UV spectrum of Benfotiamine, pyridoxamine 
and resveratrol was recorded in HPTLC scanner and maximum wavelength was 
found to be 285nm. This wavelength was selected for the study. 
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Detection of optimum mobile phase  
         A mobile phase system that would give dense compact spots and good 
separation from solvent and application position was to be selected. Initially, 
different solvent systems were tried and there observations were as given below: 
Table 1: SELECTION OF MOBILE PHASE 
Solvent system tried Observation 
Methanol: Ethanol: Chloroform: 
Acetone(1:1:5:3v:v:v:v) Drugs move along with solvent front. 
Methanol: Ethanol: Ether: 
Acetone(0.5:0.5:6:3v:v:v:v) 
Pyridoxamine dihydrochloride and 
resveratrol spot separated and 
benfotiamine did not moved from starting 
position. 
Methanol: Ethanol: Ether: Acetone:  
water(0.5:0.5:6:3v:v:v:2drops) 
Pyridoxamine dihydrochloride and 
resveratrol spot separated and 
benfotiamine did not moved from starting 
position. 
Methanol: Ether: Acetone: 
water(0.5:6.5:3v:v:v:2 drops) 
Pyridoxamine dihydrochloride and 
resveratrol spot separated and 
benfotiamine  did not moved from starting 
position. 
Methanol: Ether: 
Acetone(0.5:6.5:3v:v:v) Drugs move along with solvent front 
Tetrahydrofuran: Chloroform: 
Isopropyl alcohol( 1:8:1v:v:v) 
Pyridoxamine dihydrochloride and 
resveratrol move along with solvent front 
and benfotiamine did not moved from 
starting position. 
Methanol: Ethanol: Ether: Acetone: 
Glacial acetic 
acid(0.5:0.5:5.5:3:0.5v:v:v:v:v) 
Pyridoxamine dihydrochloride and 
resveratrol move along with solvent front 
and benfotiamine did not moved from 
starting position. 
Methanol: Ethanol: Ether: Acetone: 
Ammonia(0.5:0.5:6:3v:v:v:v:2 
drops) 
Pyridoxamine dihydrochloride and 
resveratrol move along with solvent front 
and benfotiamine did not moved from 
starting position. 
Methanol: Ethanol: Ether: Acetone: 
Triethylamine(0.5:0.5:6:3v:v:v:v:2 
drops) 
Pyridoxamine dihydrochloride and 
resveratrol move along with solvent front 
and benfotiamine did not moved from 
starting position. 
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Solvent system tried Observation 
Glacial Acetic acid: Ether: Acetone: 
Triethylamine(7:2:1v:v:v:2 drops) Drugs retained, tailed spot 
Glacial Acetic acid: Ether: Acetone: 
Triethylamine(8:1:1v:v:v:2 drops) Drugs retained, tailed spot 
Glacial Acetic acid: Ether: Acetone: 
Triethylamine(6:2:2v:v:v:2 drops) Drugs retained, tailed spot 
Glacial Acetic acid: Ether: Acetone: 
Triethylamine(6:3:1v:v:v:2 drops) Drugs retained, tailed spot 
Glacial Acetic acid: Ether: Acetone: 
Triethylamine(5:4:1:v:v:v:2 drops) Drugs retained, tailed spot 
Glacial Acetic acid: Ether: Acetone: 
Triethylamine(6:3:1v:v:v:4 drops) Drugs retained, tailed spot 
Glacial Acetic acid: Ether: Acetone: 
Triethylamine(5:4:1v:v:v:2 drops) Drugs retained, tailed spot 
Glacial Acetic acid: Ether: Acetone: 
Triethylamine(5.5:3:1:0.5v:v:v:v) Drugs retained, tailed spot 
Glacial Acetic acid: Ether: Acetone: 
Triethylamine(5:3:1:1v:v:v:v) Drugs retained, tailed spot 
Glacial Acetic acid: Ether: Acetone: 
Triethylamine(5.5:2:2:0.5v:v:v:v) Drugs retained, tailed spot 
Glacial Acetic acid: Ether: Acetone: 
Triethylamine(5.5:1:3:0.5v:v:v:v) Drugs retained, tailed spot 
Glacial Acetic acid: Ether: Acetone: 
Triethylamine(6:2:2v:v:v:4 drops) Drugs retained, tailed spot 
Glacial Acetic acid: Ether: Acetone: 
Triethylamine(6:1.5:2.5v:v:v:4 
drops) 
Drugs retained, tailed spot 
Glacial Acetic acid: Ether: Acetone: 
Triethylamine(5.5:1.5:2.5:0.5v:v:v:v) Drugs retained, tailed spot 
Glacial Acetic acid: Ether: Acetone: 
Triethylamine(5.5:1.5:2.6:0.4v:v:v:v) Drugs retained, tailed spot 
Glacial Acetic acid: Ether: Acetone: 
Triethylamine(4:2:3.5:0.5v:v:v:v) Drugs retained, tailed spot 
Glacial Acetic acid: Ether: Acetone: 
Triethylamine(4:1:4.5:0.5v:v:v:v) Drugs retained, tailed spot 
Glacial Acetic acid: Ether: Acetone: 
Triethylamine(4:0.5:5:0.5v:v:v:v) Drugs retained, tailed spot 
Glacial Acetic acid: Ether: Acetone: 
Triethylamine(5.5:1.5:3v:v:v:5 Drugs retained, tailed spot 
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Solvent system tried Observation 
drops) 
Glacial Acetic acid: Ether: 
Acetone: Triethylamine: Tetra 
butyl ammonium 
bromide(5.5:1.5:3v:v:v:5 drops:2 
drops) 
Good separation all  three  drugs with  
compact spot. 
 
Separation using glacial Acetic acid: Ether: Acetone: Triethylamine: Tetra 
butyl ammonium bromide  
Different ratios of Glacial acetic acid: Ether: Acetone: Triethylamine: 
Tetra butyl ammonium bromide was tried, from which the ratio of 
(5.5:1.5:3v/v:5drops:2drops) was selected because it gave good separation with 
compact spots and three times check mobile phase the same separation in UV 
chamber. The peaks are symmetric with acceptable Rf value. 
Optimization of chamber saturation  
The above fixed mobile phase was added to one side of twin trough 
chamber previously rinsed with acetone and dried then saturation times from 15 
minutes. 
Fixed Experimental Conditions 
Stationary phase           : Pre-coated silica gel G60F254 on aluminum sheets 
Mobile phase                     : Glacial acetic acid: Ether: Acetone: Triethylamine: 
Tetra butyl Ammonium bromide 
 Chamber saturation time   :  15 min 
 Plate migration distance   : 80mm 
 Band width                       : 6mm 
Experimental Method 
 
 
 
 
 
Department of  Pharmaceutical Analysis  33 
 Slit dimension                  :  5 × 0.45mm 
 Source of radiation          : Deuterium lamp 
 Rf value                          :  0.12, 0.33, 0.86±0.02 
 Detection wavelength     :  285nm 
Preparation of stock solutions 
Stock solutions prepared in ratio (2:1:1) of Benfotiamine (200µg/ml), 
Pyridoxamine dihydrochloride (100µg/ml) and Resveratrol (100µg/ml) was 
prepared with methanol in 10ml volumetric flask. 
 
VALIDATION OF THE METHOD: 
The developed method was validated as per ICH guidelines. The validated 
method was carried out in terms of linearity, accuracy, precision, repeatability, 
LOD and LOQ. 
Linearity and range: 
The linearity of response for the stock solution was assessed using 
different volume of stock solution. Via., 1, 2, 3, 4, 5, 6µl were spotted on TLC 
plate to obtain the concentration of 100-600ng/spot. The spots were developed and 
evaluated densitometrically using CAMAG HPTLC system. Peak area were noted 
for each spot and plotted against concentration to get a linear graph. 
 Accuracy: 
 Accuracy of method was ascertained by performing recovery at two 
concentration level of 50% and 100% by spiking standard solution (400ng and 
600ng) to the dosage form (600ng/band). A recovery study was performed in 
triplicate.   
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Precision: 
Precision of the method was studied by 
 Intra-day precision  
 Inter-day precision  
 Repeatability precision 
Repeatability of sample measurement 
Repeatability of sample application 
Intra-day precision: 
 Intra-day precision was studied by carrying out the analysis of the 
standard drug of two different concentrations for three times on the same day and 
%RSD was calculated. 
Inter-day precision: 
       Inter-day precision was studied by carrying out the analysis of the standard 
drug of two different concentrations for three different days over a period of one 
week and %RSD was calculated. 
Repeatability: 
Repeatability of sample measurement: 
       Repeatability of measurement was determined by spotting 600ng/spot of 
drug solution on a pre-coated TLC plate and developed the plate and scanned six 
times and %RSD was calculated. 
Repeatability of sample application: 
      Repeatability of sample application was carried by spotting 6 times of 4µl 
of drug solution on pre-coated TLC plate followed by development of plate and 
%RSD was calculated. 
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Limit of detection (LOD) and limit of quantification (LOQ): 
       The lowest concentration detected (LOD) and lowest concentration 
quantified (LOQ) were estimated from the set of five calibration curves used to 
determine method linearity. 
LOD = 3.3×σ/S and LOQ = 10×σ/S 
Where, σ = the standard deviation of y intercepts of regression lines 
 S = the slope of the calibration curve 
Robustness: 
The effect of deliberate variations on method parameters like the 
composition of the mobile phase saturation time, development distance spot 
scanning time interval, wavelength scan time from spotting to chromatography 
and mobile phase volume was evaluated.   
Specificity: 
The peak purity of Benfotiamine was assessed by comparing its respective 
spectra at the three different levels, that is, peak start (S), peak apex (M) and peak 
end (E) positions of the spot. 
Stability studies: 
When the developed chromatographic plate is exposed to atmosphere, the 
analytes are likely to decomposed. It is necessary to study the stability of drug on 
plate. It was studied by scanning the plate at different time interval and peak areas 
were compared with the peak area of freshly scanned plate. The developed plate 
was found to be stable for about 24 hours for benfotiamine. 
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ANALYSIS OF TABLET FORMULATION 
To determine the amount of Benfotiamine, Pyridoxamine dihydrochloride 
and Resveratrol in tablet dosage form (label claim 50, 25, 25mg per tablet 
respectively) 20 tablets were weighed, their mean weight was determined, and 
they were finely powdered. An accurately weighed powder sample equivalent to 
10mg of Pyridoxamine dihydrochloride, Resveratrol and 20mg of Benfotiamine 
was transferred into a 10ml volumetric flask then added 5ml methanol, followed 
by sonication for 10 min and further dilution up to the mark with methanol. The 
resulting solution was filtered through whattmann filter paper and three 
microliters of the filtered solution (600ng/spot) was applied on the TLC plate 
followed by development and scanning as per optimized chromatographic 
conditions. 
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IV. DEVELOPMENT AND VALIDATION OF RP-HPLC 
METHOD FOR ESTIMATION OF BENFOTIAMINE IN 
COMBINATION WITH PYRIDOXAMINE DIHYDRO-
CHLORIDE AND RESVERATROL TABLET 
FORMULATION  
 
Chromatographic method for separation: 
      Since the drug Benfotiamine, Pyridoxamine dihydrochloride and 
Resveratrol is polar in nature, RP-HPLC method was selected as separation 
technique. 
Selection of solvent: 
      The drugs are soluble in methanol and also showed good stability. Hence 
methanol was selected as the solvent. 
Selection of wavelength: 
       Good analytical separation can be obtained only by careful selection of 
wavelength for the detection. This choice requires knowledge of the UV spectrum 
of the sample component. A UV spectrum of Benfotiamine, Pyridoxamine 
dihydrochloride and Resveratrol was recorded in methanol and the overlays have 
shown good maximum absorbance at 254nm for all three drugs and it was selected 
for the study. 
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OPTIMIZATION OF CHROMATOGRAPHIC CONDITIONS  
Optimization of mobile phase: 
    Optimization of mobile phase was carried out in order to obtain ideal peak 
of benfotiamine, pyridoxamine dihydrochloride and resveratrol. 
     The mobile phase system consisting of potassium dihydrogen phosphate 
(KH2PO4) and methanol and acetonitrile was optimized for their ratio and pH of 
the buffer. 
Effect of mobile phase ratio: 
     The effect of ratio was studied by varying strength such as given below,  
Mobile phase solvent Ratio 
Binary pumps used mobile phases 
10: 90, 20: 80 & 
40: 60 
50: 50, 20: 80 & 
30: 70 Buffer: 
Acetonitrile % v/v 
Buffer: Methanol 
% v/v 
Isocratic pumps used mobile phases 
Buffer: Methanol: Acetonitrile % v/v 
50: 25+25, 50: 35+15, 60: 40, 65: 
17.5+17.5 & 70: 15+15 
 
Effect of pH:  
    Keeping the ratio of mobile phase constant (70:15+15 % v/v), the 
chromatograms were recorded at different pH between 3- 5.20. A good resolution 
and symmetrical peak was obtained at a pH of 4.90 and selected for further 
studies. 
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FIXED CHROMATOGRAPHIC CONDITIONS 
Chromatographic method    :  RP-HPLC 
Column (stationary phase)  :  LichroCart®250-4 column 
Mobile phase                       : 10mM KH2PO4: Methanol + Resveratrol       
Ratio of mobile phase : 70: 15 + 15v/v 
Detection of wavelength     : 254nm  
Flow rate      : 1.0ml/min 
Retention time : 2.20, 4.28 and 20.68± 0.02min. 
Temperature  : Room temperature 
Chromatographic development procedure: 
The HPLC system was stabilized for 40min, by passing mobile phase and 
detector was set as 254nm and flow rate of 1.0ml/min was maintained to get a 
stable baseline. One blank followed by six replicate of a single standard solution 
were injected to check the system suitability. 
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VALIDATION OF THE METHOD  
The developed HPLC method was validated according to ICH guidelines 
in terms of specificity, linearity, accuracy, precision, robustness and LOD and 
LOQ. 
Specificity: 
The specificity of the method towards the drug was established through 
study of resolution factor of the drug peak from the nearest resolving peak. The 
peak purity of BEN, PYR, and RES was determined by comparing the spectrum at 
three different regions of the spot i.e. peak start (S), peak apex (M) and peak end 
(E). Effect of excipients of formulation was studied for whether it interfered with 
the assay.         
Linearity and range: 
The mixed standard stock solution (200µg/ml of BEN, 100µg/ml of PYR 
and RES) was further diluted to get BEN, PYR and RES concentration in the 
range of 10-50µg/ml and 5-25µg/ml respectively. Linearity of the method was 
studied by injecting six concentration of the drug prepared in the mobile phase in 
triplicate into the LC system keeping the injection volume constant,  The  peak 
areas were plotted against the corresponding concentration to obtain the 
calibration graphs.  
Accuracy: 
      Accuracy of the method was carried out by applying the method to drug 
sample ( BEN, PYR and RES combination tablet) to which known amount of 
BEN, PYR and RES standard powder corresponding to 50 and 100% of label 
claim had been added (standard addition method) mixed and the powder was 
extracted and analyzed by running chromatogram in optimized mobile phase. 
Experimental  Section 
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Precision: 
The precision of the method was verified by intraday, interday and 
repeatability precision studies. 
 Intra-day precision 
 Inter-day precision  
 Repeatability  
Intra-day precision: 
Intraday precision was determined by injecting standard solutions in 
between linearity range (20, 30µg/ml for BEN and 10, 15µg/ml for PYR and RES) 
were injected three times on the same day and % RSD was calculated. 
Inter-day precision: 
Inter-day precision was determined by injecting standard solutions in 
between linearity range (20, 30µg/ml for BEN and 10, 15µg/ml for PYR and RES) 
were injected for three days and % RSD was calculated. 
Repeatability: 
Repeatability studies were performed by analysis of different 
concentration 10µg/ml of BEN and 5µg/ml of PYR and RES six times on the 
same day and %RSD was calculated. 
Limit of detection (LOD) and Limit of quantitation (LOQ): 
Limits of detection (LOD) and quantification (LOQ) represent the 
concentration of the analyte that would yield signal-to-noise ratios of 3 for LOD 
and 10 for LOQ respectively. 
Experimental  Section 
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LOD is the lowest concentration of the analyte that can produce a response 
detectable above the noise level of the system. 
     S/N = 2/1 or 3/1 
LOQ is the lowest of the analyte that can be accurately and precisely 
measured. 
        S/N = 10/1 
Robustness of method: 
        To evaluate robustness of a HPLC method, few parameters were 
deliberately varied. The parameters included variation of flow rate, percentage of 
methanol in the mobile phase and solvents. The response factors like retention 
time, resolution, asymmetric factor for these changed conditions were noted. 
Stability of solution: 
       The standard solution of benfotiamine, pyridoxamine and resveratrol kept 
under room temperature. It was injected periodically. Stability was studied by 
looking for any change in retention time, resolution and peak shape, when 
compared to chromatogram of freshly prepared solution. The solution was stable 
24hrs under room temperature. 
System suitability parameters: 
       The system suitability parameters like peak area, tailing factor, theoretical 
plate count, and resolution and retention time were calculated from the standard 
chromatograms. 
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Analysis of a marketed formulation: 
To determine the content of BEN, PYR and RES in conventional tablet 
(brand name: Ageless, label claim 50mg of BEN, 25mg of PYR and RES per 
tablet) twenty tablets were weight, their mean weight determined and finely 
powdered. The weight of the tablet triturate equivalent to 20mg of BEN and 10mg 
of PYR and RES was transferred into a 10ml volumetric flask containing 6ml 
methanol, sonicated for 5min and diluted up to 10ml with methanol. The sample 
solution was then filtered using 0.45µm filter. The above stock solution was 
further diluted to get sample solution of 20µg/ml BEN and 10µg/ml PYR and 
RES respectively. A 20µl volume of sample solution was injected into HPLC, six 
times, under the conditions described above. The peak areas were measured at 
254nm.  
  
 Results & Discussion 
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RESULTS AND DISCUSSION 
I. DEVELOPMENT AND VALIDATION OF UV 
SPECTROSCOPIC METHOD FOR THE ESTIMATION OF 
BENFOTIAMINE IN BULK DRUG AND TABLET 
FORMULATION 
The stock solution containing 1000µg/ml of Benfotiamine was diluted 
using methanol to get a concentration of solution 10µg/ml. The resulting solution 
was scanned in the UV spectrometer in the range of 200-400nm. The maximum 
absorbance was found to be at 240nm. The conjugated chromophore system of 
Benfotiamine shown smooth and it is shown fig 1.  
Fig 1: UV spectrum of Benfotiamine in methanol 
  
 
VALIDATION PARAMETERS  
Linearity and range  
       The stock solution of Benfotiamine was diluted to get the concentration of 4-
24µg/ml. The absorbance of these solutions was noted at selected λ max of 
240nm. The calibration curve was plotted using concentration versus absorbance 
(fig 2 and table 1). The slope, intercept and correlation coefficient values were 
0.034, 0.0016 and 0.9990, respectively. The overlay spectra of standards shown in 
fig 3. 
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VALIDATION PARAMETERS  
Linearity and range: 
 A calibration graph concentration between range of Benfotiamine (2-
24µg/ml) and its absorbance shown in fig, 2. The calibration data table shown in 
table 1. The slope, intercept and correlation coefficient values were 0.034, 0.0016 
and 0.9990, respectively. The overlay spectrum of all concentration shown in 
fig,3. 
                     Fig 2: Calibration graph of Benfotiamine (4-24µg/ml) 
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                       Table 1: Calibration table for Benfotiamine (4-24µg/ml) 
                   Concentration (µg/ml)                        Absorbance  
                                 4                            0.1512 
                                 8                            0.2776 
   12                            0.3959 
                                16                            0.5474 
                                20                            0.6884 
                                24                            0.8368 
 
Fig 3: Overlay spectrum of Benfotiamine 
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Precision:  
The method precision was obtained by determining the assay by preparing 
six sample of selected concentration its 12 & 16µg/ml of Benfotiamine. The 
method precisions for intraday, interday, repeatability were studied and %RSD are 
shown in table 2,3&4, respectively. 
Table 2: Intra-day precision 
Concentration(µg/ml) Absorbance %RSD 
 
12 
 
0.4010 
0.29 0.4026 
0.4035 
 
16 
 
0.5458 
 
0.21 
0.5468 
0.5482 
 
Table 3: Inter-day precision 
Concentration(µg/ml) Absorbance %RSD 
 
12 
 
0.4018 
 
0.09 
0.4026 
0.4022 
 
16 
 
0.5678 
0.08 0.5687 
0.5678 
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Table 4: Repeatability 
Concentration(µg/ml) Absorbance %RSD 
12 
0.4010 
0.19 
0.4026 
0.4035 
0.4018 
0.4026 
0.4022 
Solution stability: 
The working standard solutions of Benfotiamine were stored at room 
temperature and refrigerated. They were analyzed at different time interval. From 
the absorbance noted it was seen that the solution is stable up to 24hrs at room 
temperature (table 5). The solution stored under refrigeration was found to be 
stable up to 30hrs. 
Table 5: Solution stability 
 
Concentration(µg/ml) Time(hours) Absorbance 
 
12 
0 0.4010 
3 0.4026 
6 0.4035 
12 0.3959 
24 0.3902 
30 0.3752 
 
 Results & Discussion 
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ANALYSIS OF FORMULATION: 
   The solution of formulation was prepared and UV spectra was recorded 
and shown in fig 4. The amount present per tablet, % label claim, and %RSD were 
calculated and presented in table 6. The result obtained by UV spectroscopic 
method for Benfotiamine is satisfiable and there was no interference due to 
excipients. 
Fig 4: UV spectrum of Benfotiamine formulation 
 
Table 6: Results of analysis of formulation 
Trade name Amount of drug/ tab 
% label 
claim % RSD SEM 
Benalgis 
 
Labeled Found 
99 0.87 0.03 
100mg 99mg 
*Average of six observation  
 Results & Discussion 
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Recovery study: 
Recovery studies were carried out at 50% and 100% levels. The 
percentage recovery and percentage RSD of the results were calculated and shown 
in table 7. They were found to be good. 
Table 7: Recovery study 
Level % recovery % RSD SEM 
50% 96.54% 0.35 0.16 
100% 98.87% 0.69 0.22 
*Average of six observation 
Results & Discussion 
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II.  DEVELOPMENT AND VALIDATION OF STABILITY 
INDICATING HPTLC METHOD FOR THE DETERMINATION OF 
BENFOTIAMINE AND ITS APPLICATION OF ACCELERATED 
STABILITY STUDIES OF BENFOTIAMINE TABLETS  
Method development and optimization for stability indicating HPTLC 
method 
 Different mobile phase compositions are tried for development and 
validation of benfotiamine by stability indicating HPTLC method. Among these 
mobile phase systems, Glacial acetic acid: Methanol: Triethylamine (9:1 
%v/v: 2drops) was selected because in this system compact spot and dense spot 
with good separation were obtained. 
 METHOD VALIDATION 
  The results of validation of the stability indicating method of Benfotiamine 
using Glacial acetic acid: Methanol: Triethylamine (9:1%v/v: 2drops) as the 
mobile phase are described below. 
Linearity and range  
Linear regression data showed a good correlation coefficient over a 
concentration range of 200-1200ng/spot. The calibration data are shown in table 8, 
and the slope, intercept and correlation coefficient values were found are 
presented in table 9. The calibration graph is shown fig 5. The standard spectrum 
and chromatograms obtained at different concentrations of Benfotiamine are 
shown in fig 6-12. 
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Table 8: Calibration data for Benfotiamine 
Concentration (ng/spot) Peak area 
200 1628.2 
400 2733.0 
600 3658.4 
800 4562.3 
1000 5367.3 
1200 6176.0 
 
Table 9: Slope, intercept & correlation coefficient values 
Slope 23.368 
Intercept -0.133 
Correlation coefficient 0.998 
  
Fig 5: Calibration graph of benfotiamine (200-1200µg/ml) 
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Standard spectrum and chromatograms 
Fig 6: Spectrum of Benfotiamine 
 
Fig 7: Benfotiamine 200ng/spot 
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Fig 8: Benfotiamine 400ng/spot 
 
Fig 9: Benfotiamine 600ng/spot 
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Fig 10: Benfotiamine 800ng/spot 
 
Fig 11: Benfotiamine 1000ng/spot 
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Fig 12: Benfotiamine 1200ng/spot 
 
Precision 
  The results of repeatability of sample application and sample measurement 
are given in the table 10 and 11. The tables 12 and 13 summarizes the results of 
intra-day and inter-day precision. The % RSD values were found to be less than 2. 
Table 10: Repeatability of sample application 
Concentration(ng) Peak area %RSD 
 
 
 
600 
 
 
3658.4  
 
0.57 
3666.3 
3480.7 
3618.8 
3654.8 
3643.4 
  
Results & Discussion 
 
 
 
Department of  Pharmaceutical Analysis  57 
Table 11: Repeatability of measurement 
Concentration(ng) Peak area %RSD 
 
 
200 
 
 
1628.2  
 
1.13 
 
1640.2 
1643.1 
1682.3 
1640.3 
1652.9 
Table 12: Intraday precision 
Concentration(ng) Peak area %RSD 
 
400 
 
2712.0 
 
0.58 2733.0 
2701.5 
 
800 
 
4562.3 
 
0.36 
 
4571.7 
4594.6 
Table 13: Interday precision 
Concentration(ng) Peak area %RSD 
 
400 
 
2601.0  
0.38 2621.9 
2617.0 
 
800 
 
4503.6  
0.61 4559.1 
4529.3 
Limit of detection (LOD) and Limit of quantification (LOQ) 
LOD and LOQ were determined by applying decreasing amount of the 
drug in triplicate on the plate. The lowest concentration at which the peak is 
detected is called ‘limit of detection’ which was found out to be 10ng/spot. 
     The lowest concentration at which peak is quantified is called ‘limit of 
quantification’ which was found to be 50ng/spot. 
Results & Discussion 
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Robustness  
The robustness of the method is its ability to remain unaffected by small 
changes in the parameter such as ratio of mobile phase and saturation time. The 
method is said to be robust as minor variation (as shown below) not affected 
quantification. 
                   Parameters                     Observation  
Ratio of mobile phase ( Glacial Acetic 
acid: Methanol: 
Triethylamine(8:2v/v:2drops ±0.1ml,) 
Very slight changes in Rf but no 
change in  peak area 
Saturation time(15 ±0.1, minutes)   peak symmetry retained. 
 
Stability studies  
Stability of chromatographic plate 
    When the developed method chromatographic plate was expose to 
atmosphere, the analytes are likely to decompose. Hence it is necessary to conduct 
stability studies of the plate.  
Stability of the analyte on the plate was studied at different time intervals 
and peak areas were compared with peak area of freshly scanned plate. The 
developed plate was found to be stable for less than 24hrs, (stable 14). 
Table 14: Stability of chromatographic plate 
Time (hr) Concentration(ng/spot) Peak area 
 
0 
200 1628.2 
3658.4 600 
 
12 
200 1478.1 
3447.4 600 
 
24 
200 1425.1 
3406.6 600 
Results & Discussion 
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ANALYSIS OF FORMULATION 
Preparation of sample solution for benfotiamine: 
 Each of 20 tablets containing 100mg of Benfotiamine was taken for the 
study and average weight was determined. Quantity equivalent to 10mg 
Benfotiamine was weighed and transferred into a 10ml standard flask and after 
dissolving it was made up to volume with methanol. It was filtered and used for 
analysis. 
Recording chromatogram: 
 The fixed chromatographic condition, a suitable volume of sample solution 
was applied on the precoated TLC plate. The plate was analyzed and 
chromatogram as recorded. The amount present per tablet, % label claim were 
calculated and shown in table 15, and chromatogram shown in fig 13. 
Fig 13: Chromatogram of Benfotiamine formulation 
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Table 15: Results of analysis formulation 
Brand name 
Amount of 
drug/tab % label 
claim % RSD SEM 
Labeled Found 
Benalgis 100mg 98.54mg 98.54% 0.98 0.13 
*Average of six observations  
Rovers: 
Recovery studies were carried out at 50% and 100% levels. The 
percentage recovery and percentage % RSD of the results were calculated and 
shown in table 16. The value proves the accuracy of the method 
Table 16: recovery 
Level % recovery % RSD SEM 
50% 92.36% 0.28 0.23 
100% 95.25% 0.86 0.11 
*Average of six observations  
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Forced degradation studies: 
HPTLC studies of samples obtained by stress testing of benfotiamine 
under different conditions suggested the following degradation behavior. 
Acid hydrolysis: 
 Under given conditions of acid hydrolysis(0.01N HCL), it was found that 
at 0 hour 6.17% of the drug degraded (fig, 14) and on further degradation, i.e. 
after refluxing at 40ºC 2 hour 10% degradation was found out (fig, 15) and after 
highest 5 hour 13% drug degradation was found out (fig, 16). No degradant peak 
was found in the chromatogram. 
Fig 14: Acid hydrolysis at 0 hour 
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Fig 15: Acid hydrolysis at 2 hour 
 
Fig 16: Acid hydrolysis at 5 hour 
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Alkaline hydrolysis: 
  In alkaline hydrolysis (0.01N NAOH), it was observed that 17.03% of the 
drug degraded at 0 hour, (fig, 17). On further degradation it was found that after 
refluxing at 40ºC for 5 hour 13.15% of the degraded (fig, 18). No degradation 
products were observed. 
Fig 17: Alkaline hydrolysis at 0 hour 
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Fig 18: Alkaline hydrolysis at 5 hour 
 
Oxidative degradation  
 The drug was also found to be susceptible to oxidation degradation. Here 
with 30% H2O2, at 0 hour it shows 25.16% degradation (fig 19), and up on further 
degradation, i.e., after refluxing for 5 hours at 40ºC it shows about 42.37% 
degradation without any degradation peak fig 20. 
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Fig 19: Oxidative degradation at 0 hour 
 
Fig 20: Oxidative degradation at 5 hour 
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   The drug shows extensive degradation in acid, alkaline and oxidative 
degradation respectively (Table 17) presents the result of the studies. 
Table 17: Results of degradation studies of Benfotiamine 
Type of stress Condition 
% degradation 
Rf 
0 hour 5 hour 
Acid hydrolysis 0.01 N HCL 6.01% 11.30% 0.29 
Alkaline  hydrolysis 0.01 N NAOH 17.03% 5.44% 0.29 
Oxidation 30% H2O2 25.16% 42.37% 0.29 
  
 Forced degradation studies resulted in considerable degradation as 
evidenced by the reduction in the peak area when subjected to acid/base/oxidation 
degradation. The degradants formed were not detected but showed a marked 
decrease in the peak area of the parent drug. No significant change in the Rf value 
shows the evidence for the analyte peak after significant degradation.  
Degradation of placebo in formulation: 
   The fixed chromatographic condition was applied to estimate placebo 
inactive ingredients. The placebo was subjected for acid/base hydrolysis and 
oxidation and used the some excipients in degradation study. The results 
chromatogram given below, fig 21. There was an interference seen at Rf 0.36 
which was not interfering with benfotiamine Rf value (0.29). 
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Fig 21: Alkaline hydrolysis placebo at 0 hour 
 
Degradation of Benfotiamine in formulation: 
  From the various stress samples prepared 0.6µl was spotted on TLC plate 
in triplicates analyzed using fixed chromatographic conditions described earlier. 
(Fig, 22,-24). 
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Fig 22: Acid hydrolysis of formulation 
 
Fig 23: Alkaline hydrolysis of formulation 
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Fig 24: Oxidative degradation of formulation 
 
 
Amount of benfotiamine reminded after degradation studies: 
Degradation studies 
Maximum degradation 
time % of Benfotiamine 
remaining 
interferents Temperature Retention time 
Acid hydrolysis 40ºC 4 hours Rf -29 7.79 
Alkaline hydrolysis 40ºC 4 hours Rf -29 61.23 
Oxidative degradation 40ºC 4 hours Rf -29 66.25 
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III.  DEVELOPMENT AND VALIDATION OF HPTLC METHOD FOR 
ESTIMATION OF BENFOTIAMINE IN COMBINATION WITH 
PYRIDOXAMINE DIHYDROCHLORIDE AND RESVERATROL 
IN COMBINED DOSAGE FORM 
 
Among various mobile phase system tried the one contain a mixture of 
Glacial acetic acid: Ether: Acetone: Triethylamine: Tetra butyl ammonium 
bromide (5.5:1.5:3 % v/v: 5 drops: 2 drops) gave compact dense spot was chosen 
for the estimation of benfotiamine by HPTLC method. The plate used was pre-
coated silica gel G60F254. The method was for the validated and details given 
below. 
Linearity and range: 
   A 200µg/ml and 100µg/ml of BEN, PYR and RES was prepared in methanol. 
Aliquots of this solution (1-6µl) were applied on the plate. The plate was 
developed, scanned and peak areas were noted. Linear regression data showed 
good correlation coefficient over a concentration range of (200-1200ng/spot and 
100-600ng/spot). The calibration graphs are shown in fig 25, 26 and 27. The 
slope, intercept, and correlation coefficient values were in noted respectively 
(table 18). The spectra recorded on HPTLC scanner and the standard densitograms 
are shown in fig.28 to 31, and calibration data were shown table, 19, 20, and 21.  
Table 18: Regression data 
Linear regression Benfotiamine Pyridoxamine Resveratrol 
Slope 5753 3053.43 11440.3 
Intercept -241.4 -90.4 -696.2 
Correlation 
coefficient 0.998 0.997 0.998 
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Table 19: Calibration data for Benfotiamine 
Concentration (ng/spot) Peak area 
200 948.5 
400 2093.5 
600 3242.6 
800 4089.8 
1000 5626.1 
1200 6713.7 
 
Fig 25: Calibration graph of Benfotiamine (200-1200ng/spot) 
 
Concentration (ng/ml) 
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Table 20: Calibration data for Pyridoxamine dihydrochloride  
Concentration (ng/spot) Peak area 
100 281.8 
200 680.5 
300 902.3 
400 1330.9 
500 1691.4 
600 1607.4 
 
Fig 26: Calibration graph of Pyridoxamine dihydrochloride (100-600ng/spot) 
 
Concentration (ng/ml) 
 
 
Results & Discussion 
 
 
 
 
Department of  Pharmaceutical Analysis   73 
Table 21: Calibration data for Resveratrol 
Concentration(ng/spot) Peak area 
100 454.8 
200 1441.9 
300 3310.1 
400 3923.9 
500 4977.8 
600 6138.7 
 
Fig 27: Calibration graph of Resveratrol (100-600ng/spot) 
 
 
 
) 
 
 
 
 
 
Concentration (ng/ml) 
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Fig 28: Spectrum of Benfotiamine 
 
Fig29: Spectrum of Pyridoxamine dihydrochloride 
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Fig 30: Spectrum of resveratrol 
 
Fig 31: Chromatogram of Benfotiamine, Pyridoxamine dihydrochloride  
and Resveratrol 
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Precision 
 The method precision was obtained by determining the assay by preparing 
six samples of selected concentration (600 & 1000ng/spot) of Benfotiamine and 
300 & 500ng/spot Pyridoxamine dihydrochloride and Resveratrol. The % RSD 
calculated for method precision of inter-day, intra-day (table 22, 23 and 24) and 
repeatability (repeatability of sample measurement and sample application 
respectively) are shown in table 25, 26 and 27. 
Table 22: Intra-day and inter-day precision of Benfotiamine 
Concentration (ng/spot) 
 
Peak area %RSD 
Intra-day Inter-day Intra-day Inter-day 
 
600 
3242.6 3230.8  
0.58 
 
1.34 3218.7 3291.3 
3256.5 3263.3 
 
1000 
5626.1 5523.7  
0.19 
 
0.16 5617.4 5545.7 
5639.2 5587.4 
 
Table 23: Intra-day and inter-day precision of Pyridoxamine dihydrochloride 
Concentration (ng/spot) 
 
Peak area %RSD 
Intra-day Inter-day Intra-day Inter-day 
 
300 
719.8 704.7  
0.62 
 
0.62 714.5 708.3 
710.9 699.5 
 
500 
1258.7 1153.8  
0.64 
 
1.44 1262.2 1132.2 
1264.8 1121.5 
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Table 24: Intra-day and inter-day precision of Resveratrol 
Concentration (ng/spot) Peak area % RSD 
Intra-day Inter-day Intra-day Inter-day 
 
300 
1048.7 964.4  
1.44 
 
0.94 1062.3 953.6 
1079.3 946.5 
 
500 
2189.3 2256.8  
1.94 
 
1.32 2110.5 2280.8 
2126.1 2220.9 
 
Table 25: Repeatability of sample measurement and sample  
application of Benfotiamine 
Concentration 
(ng/spot) 
Peak area % RSD 
Sample 
measurement 
Sample 
application 
Sample 
measurement 
Sample 
application 
            400 
1531.5 1413.5 
 
        0.74 
 
     1.36 
1525.1 1452.0 
1499.3 1416.6 
1516.6 1459.6 
1519.8 1429.2 
1509.4 1449.4 
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Table 26: Repeatability of sample measurement & sample application of 
Pyridoxamine dihydrochloride 
Concentration 
(ng/spot) 
 
Peak area %RSD 
Sample 
measurement 
Sample 
application 
Sample 
measurement 
Sample 
application 
            200 
602.1 584.2 
        0.74       0.84 
614.5 599.0 
604.7 594.9 
608.0 593.2 
602.8 589.4 
607.3 592.7 
 
Table 27: Repeatability of sample measurement & sample application  
of Resveratrol 
Concentration 
(ng/spot) 
 
Peak area %RSD 
Sample 
measurement 
Sample 
application 
Sample 
measurement 
Sample 
application 
200 
1235.4 1355.0 
1.18 0.73 
1254.2 1345.4 
1224.6 1342.6 
1214.0 1332.1 
1247.3 1336.2 
1237.2 1327.6 
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Robustness  
The robustness of the method is its ability to remain unaffected by small 
changes in the parameter such as ratio of mobile phase and saturation time. The 
method is said to be robust as minor variation (as shown below) not affected 
quantification. 
Parameters Observation 
Ratio of mobile phase ± 0.1 (Acetic 
acid: Ether: Acetone: Triethylamine: 
tetra butyl ammonium 
bromide(5:5:1.5:3:5 drops: 2drop ± 
0.1ml) 
Slight changes in Rf, but no different in 
peak area  
Saturation time10  (±0.1,minutes, ) Peak symmetry retained. 
 
Stability studies  
Stability of chromatographic plate 
 When the developed method chromatographic plate was exposed to 
atmosphere, the analytes are likely to decomposed. Hence it was necessary to 
conduct stability studies of the plate.  
Stability of the analyte on the plate was studied at different time intervals 
and peak areas were compared with peak area of freshly scanned plate. The 
developed plate was found to be stable for less than 24hrs, table 28, 29, and 30. 
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Table 28: Benfotiamine 
Time (hr) Concentration(ng/spot) Peak area 
 
0 
400 
800 
2093.5 
4089.8 
 
6 
400 
800 
1616.6 
3248.0 
 
22 
400 
800 
1452.0 
3134.2 
 
Table 29: Pyridoxamine dihydrochloride 
Time (hr) Concentration(ng/spot) Peak area 
0 
200 
400 
680.8 
1330.9 
6 
200 
400 
374.9 
925.6 
22 
200 
400 
359.4 
825.6 
 
Table 30: Resveratrol 
Time (hr) Concentration(ng/spot) Peak area 
0 
200 
400 
1441.9 
3923.9 
6 
200 
400 
942.7 
3278.8 
22 
200 
400 
912.5 
3014.4 
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ANALYSIS OF FORMULATION  
Preparation of sample solution for Benfotiamine, Pyridoxamine 
dihydrochloride, Resveratrol 
      20 tablets, each containing 50mg of Benfotiamine, 25mg of Pyridoxamine 
dihydrochloride and 25mg of Resveratrol were taken for the studies and average 
weight were determined. Quality equivalent to sample was weighed and 
transferred to 10ml volumetric flask extracted and made up to volume with 
methanol. It was filtered and used for analysis, (fig, 32). 
Fig 32: Chromatogram of Benfotiamine, Pyridoxamine dihydrochloride and 
Resveratrol formulation 
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Recording chromatogram  
       With the fixed chromatographic condition, a suitable volume of sample 
solutions was applied on the precoated TLC plate. The plate was analyzed and 
chromatogram was recorded, fig 32. 
Peak areas of sample chromatograms were noticed and the amount of 
drugs was calculated, table 31.  
Table 31: Results analysis of formulation 
Brand name Amount of drug/tab 
% label 
claim % RSD SEM 
Ageless Labeled Found 
96.42% 0.74 
 
0.17 Benfotiamine 50mg 48.21mg 
Pyridoxamine 
dihydrochloride 25mg 24.15mg 96.60% 0.45 
0.03 
Resveratrol 25mg 23.48mg 93.92% 0.65 0.08 
*average of six observations 
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IV. DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR 
ESTIMATION OF BENFOTIAMINE IN COMBINATION WITH 
PYRIDOXAMINE DIHYDRO-CHLORIDE AND RESVERATROL 
TABLET FORMULATION   
   The drugs is a polar in nature hence RP-HPLC method and C18 column 
was used for the HPLC method development for the estimation of benfotiamine in 
combination of pyridoxamine dihydrochloride and resveratrol. 
Selection of wavelength: 
      Good analytical separation can be obtained only by careful selection of 
wavelength for the detection (fig.33, 34 and 35). The smooth spectrum obtained 
from which 254nm was selected for the drug. The overlay spectrum of all three 
drugs shown in fig 36. 
Fig 33: Spectrum of Benfotiamine 
 
Fig 34: Spectrum of Pyridoxamine dihydrochloride 
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Fig 35: Spectrum of Resveratrol 
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Fig 36: Overlay spectrum of Benfotiamine, Pyridoxamine dihydrochloride & 
Resveratrol 
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Selection of mobile phase: 
For developing HPLC method, mobile phase system containing potassium 
dihydrogen phosphate (pH adjusted with ortho phosphoric acid): methanol and 
acetonitrile was tried at different ratios and different pH.  The observations are 
given below, table 32. 
Table 32: Selection of mobile phase 
Mobile phase Ratio % v/v Effect of pH Observation 
10mM 
ammonium acetate: 
Acetonitrile 
10:90 4.65 
Benfotiamine, pyridoxamine 
dihydrochloride & resveratrol  
retention time is same 
BEN- symmetry peak 
PYR- symmetry peak 
RES- peak tailing 
10mM ammonium 
acetate: Acetonitrile 20:80 4.62 
Benfotiamine, pyridoxamine 
dihydrochloride & resveratrol  
retention time is same 
BEN- symmetry peak 
PYR- peak tailing 
RES- peak tailing 
10mM ammonium 
acetate: Acetonitrile 20:80 3.05 
Benfotiamine, pyridoxamine 
dihydrochloride & resveratrol  
retention time is same 
EN- peak tailing 
PYR- peak tailing 
RES- peak tailing 
10mM ammonium 
acetate: Acetonitrile 20:80 3.50 
Benfotiamine, pyridoxamine 
dihydrochloride & resveratrol  
retention time is same 
BEN- peak tailing 
PYR- peak tailing 
RES- peak tailing 
Results & Discussion 
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Mobile phase Ratio % v/v Effect of pH Observation 
10mM ammonium 
acetate: Acetonitrile 20:80 2.80 
Benfotiamine, pyridoxamine 
dihydrochloride & resveratrol  
retention time is same 
BEN- peak tailing 
PYR- peak tailing 
RES- peak tailing 
10mM ammonium 
acetate: Acetonitrile 40:60 2.80 
Benfotiamine, pyridoxamine 
dihydrochloride & resveratrol  
retention time is same 
BEN- peak tailing 
PYR- peak tailing 
RES- peak tailing 
10mM potassium 
dihydrogen 
phosphate: 
Methanol 
20:80 5.20 
Benfotiamine, pyridoxamine 
dihydrochloride & resveratrol is 
resolution less than 2 
BEN- peak tailing 
PYR- peak tailing 
RES- peak tailing 
10mM potassium 
dihydrogen 
phosphate: 
Methanol 
20:80 4.50 
Benfotiamine, pyridoxamine 
dihydrochloride & resveratrol  
retention time is same 
BEN- peak tailing 
PYR- peak tailing 
RES- peak tailing 
10mM potassium 
dihydrogen 
phosphate: 
Methanol 
30:70 4.50 
Benfotiamine, pyridoxamine 
dihydrochloride & resveratrol  
retention time is same 
BEN- peak tailing 
PYR- peak tailing 
RES- peak tailing 
10mM potassium 
dihydrogen 
phosphate: 
50:25+
25 5.21 
Benfotiamine, pyridoxamine 
dihydrochloride & resveratrol  
retention time is separate 
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Mobile phase Ratio % v/v Effect of pH Observation 
Methanol+ 
Acetonitrile 
BEN- peak spilt 
PYR- peak tailing 
RES- peak symmetry 
10mM potassium 
dihydrogen 
phosphate: 
Methanol+ 
Acetonitrile 
50:35+
15 5.22 
Benfotiamine, pyridoxamine 
dihydrochloride & resveratrol  
retention time is separate 
BEN- peak spilt 
PYR- peak tailing 
RES- peak symmetry 
10mM potassium 
dihydrogen 
phosphate: 
Methanol+ 
Acetonitrile 
60:20+
20 5.21 
Benfotiamine, pyridoxamine 
dihydrochloride & resveratrol  
retention time is separate 
BEN- peak spilt 
PYR- peak symmetry 
RES- peak symmetry 
10mM potassium 
dihydrogen 
phosphate: 
Methanol+ 
Acetonitrile 
65:17.
5+17.5 5.21 
Benfotiamine, pyridoxamine 
dihydrochloride & resveratrol  
retention time is separate 
BEN- peak tailing 
PYR- peak symmetry 
RES- peak symmetry 
10mM potassium 
dihydrogen 
phosphate: 
Methanol+ 
Acetonitrile 
70:15+
15 5.24 
Benfotiamine, pyridoxamine 
dihydrochloride & resveratrol  
retention time is separate 
BEN- peak symmetry 
PYR- peak fronting 
RES- peak symmetry 
10mM potassium 
dihydrogen 
phosphate: 
Methanol+ 
Acetonitrile 
70:15
+15 4.90 
Good resolution between all 
drugs with acceptable peak 
shape. 
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Linearity and range: 
A calibration graph was plotted with measured peak areas against 
concentration. From the graph it was found that BEN, PYR and RES shows good 
linearity in the concentration between 10-50µg/ml for BEN, 5-25µg/ml for PYR 
and RES. The peak area of these solutions was measured at 254nm. The slope, 
intercept, and correlation coefficient values were calculated respectively (table 
33). The linearity table is shown in table 34, 35 and 36. The linear graph and 
standard chromatogram obtained are shown in fig 37 to 44. 
Table 33: Regression data 
Linear regression Benfotiamine Pyridoxamine dihydrochloride Resveratrol 
Slope 51090.8 97602.1 12488.1 
Intercept -23973.5 -16901.5 -10335.9 
Correlation coefficient 0.999 0.997 0.999 
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Table 34: Calibration data for Benfotiamine 
Concentration (µg/ml) Peak area 
10 276467 
20 596201 
30 761997 
40 1020219 
50 1240952 
 
 
Fig 37: Calibration graph of Benfotiamine (10-50µg/ml) 
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Table 35: Calibration data for Pyridoxamine dihydrochloride 
Concentration (µg/ml) Peak area 
5 172106 
10 273347 
15 365260 
20 427182 
25 517725 
 
Fig 38 : Calibration graph of Pyridoxamine dihydrochloride (5-25 µg/ml) 
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Table 36: Calibration data for Resveratrol 
Concentration (µg/ml) Peak area 
5 75019 
10 155132 
15 200955 
20 254657 
25 323061 
 
Fig 39: Calibration graph of Resveratrol (5-25µg/ml) 
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Fig 40: Chromatogram of BEN (10µg/ml), PYR and PYR (5µg/ml) 
 
Fig 41: Chromatogram of BEN (20µg/ml), PYR and PYR (10µg/ml) 
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Fig 42: Chromatogram of BEN (30µg/ml), PYR and PYR (15µg/ml) 
 
Fig 43: Chromatogram of BEN (40µg/ml), PYR and PYR (20µg/ml) 
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Fig 44: Chromatogram of BEN (50µg/ml), PYR and PYR (25µg/ml) 
 
Precision:  
Intra-day and inter-day precision: 
Intra-day and inter-day precision was determined by injecting standard 
solutions in between linearity range (20 and 30µg/ml for BEN, 10 and 15µg/ml 
for PYR and RES) were injected for three times and % RSD was calculated (table 
37, 38 and 39). 
Table 37: Intraday and interday precision of Benfotiamine 
Concentration (µg/ml) 
 
Peak area %RSD 
Intraday Interday Intraday Interday 
 
20 
593475 589287 
 
0.16 
 
0.06 592474 589054 591473 588542 
 
30 
761997 758985 
 
0.56 
 
0.53 762874 753214 769820 751208 
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Table 38: Intraday and interday precision of Pyridoxamine dihydrochloride 
Concentration (µg/ml) 
 
Peak area % RSD 
Intraday Interday Intraday Interday 
10 
273347 271245 
0.29 0.22 274852 270236 
273654 270148 
15 
365260 367854 
 
0.57 
 
1.09 361245 360214 
364153 362148 
 
Table 39: Intraday and interday precision of Resveratrol 
Concentration (µg/ml) 
 
Peak area % RSD 
Intraday Interday Intraday Interday 
10 
155132 154726 
0.98 1.32 158642 158742 
152485 155874 
15 
200955 218752 
0.94 1.24 210584 214754 
214820 213654 
 
Repeatability: 
   Repeatability of injection was determined by injecting standard solutions 
(10µg/ml) of BEN and (5µg/ml) of PYR and RES for six times, noted peak areas 
and % RSD was calculated (table 40, 41 and 42). 
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Table 40: Repeatability injection of Benfotiamine 
Concentration (µg/ml) Repeatability % RSD 
10 
276467 
1.10 
278562 
274856 
276984 
278102 
270254 
 
Table 41: Repeatability injection of Pyridoxamine dihydrochloride 
Concentration (µg/ml) Repeatability % RSD 
 
5 
 
172106 
0.18 
173258 
174852 
170235 
174714 
179680 
  
Table 42: Repeatability injection of Resveratrol 
Concentration (µg/ml) Repeatability % RSD 
5 
75019 
 
0.20 
75128 
75365 
75054 
75147 
75365 
Results & Discussion 
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Limit of detection and limit of quantification (LOD and LOQ): 
   The LOD and LOQ were found to be respectively in shown, (table 43)  
Table 43: LOD and LOQ 
Benfotiamine Pyridoxamine dihydrochloride Resveratrol 
LOD LOQ LOD LOQ LOD LOQ 
0.2µg/ml 0.7µg/ml 0.3µg/ml 0.9 µg/ml 0.3µg/ml 1µg/ml 
 
Specificity:  
  There were no additional peaks observed while injecting solvents or 
mobile phase alone. The peak purity index of standard BEN 0.9998,  PYR 0.9979 
and RES 0.9998. 
Robustness: 
In order to demonstrate the robustness of the method, the following 
optimized conditions were slightly changed.  
      ± 0.1ml flow rate  
     ± 0.5% organic solvent 
      ± 0.1 PH 
     The responses for these changed chromatographic parameters were almost 
same for the fixed chromatographic parameters and hence the developed method 
was said to be robustness. 
Stability of solution: 
    The solution under room temperature was stable for 24 hours. (Table 44) 
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Table 44: Stability of solution 
Hours 
Benfotiamine Pyridoxamine Resveratrol 
Concentration 
(µg/ml) 
Peak 
area 
Concentration 
(µg/ml) 
Peak 
area 
Concentration 
(µg/ml) 
Peak 
area 
0 hrs 20 570535 10 270137 10 159877 
6 hrs 20 577376 10 273347 10 155132 
24 hrs 20 567586 10 266242 10 148883 
 
System suitability studies: 
  The system suitability parameters like peak area, tailing factor, theoretical 
plate count, resolution, and retention time were calculated from the standard 
chromatogram (table 45). 
Table 45: System suitability studies 
Drug Theoretical plate(N) 
Retention 
time(min) 
Tailing 
factor Resolution 
Benfotiamine 3574.368 4.290 1.36 - 
Pyridoxamine 3141.052 2.195 1.40 4.790 
Resveratrol 3220.258 20.589 1.18 14.451 
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Analysis of formulation  
    Twenty tablets each containing 50mg of BEN, 25mg of PYR and RES was 
taken for the study and average weight was determined. Quantity equivalent to 
20mg of BEN, 10mg of PYR and RES was weight and transferred to 10ml 
standard flask and it was dissolved and made up to volume with methanol. Further 
dilutions were made and injected. The chromatogram is shown in fig 45. The 
result of an analysis of formulation is shown in table 46. 
Fig 45: Chromatogram of BEN, PYR and RES equivalent to 10µg/ml 
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Table 46: Analysis of formulation 
Drug Amount of drug/tab % label 
claim % RSD SEM 
Ageless Label Found 
Benfotiamine 50mg 50.5mg 101% 0.18 0.16 
Pyridoxamine 
dihydrochloride 25mg 24.2mg 96.8% 0.58 
0.15 
Resveratrol 25mg 24.8mg 99.2% 0.38 0.13 
*Average of six observation  
Recovery study: 
Recovery studies were carried out at 50% and 100% levels. The 
percentage recovery and % RSD of the results were calculated, table 47. The high 
% recovery values shows accuracy of the method. 
Table 47: Recovery study 
% Level Drug % Recovery % RSD SEM 
50 
BEN 99.61% 0.84 0.21 
PYR 98.23% 0.47 0.14 
RES 99.47% 0.36 0.23 
100 
BEN 102.21% 0.96 0.13 
PYR 101.01% 1.14 0.26 
RES 103.24% 0.54 0.14 
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STATISTICAL ANALYSIS 
 
 To ascertain the result obtain in the four methods developed, the statistical 
analysis was carried out. 
 
Unpaired‘t’ test 
Accuracy of UV method: 
The % RSD values of the UV method are shown in table 48 
                                             Table 48: % RSD of accuracy  
Parameter % RSD 
 
 
UV 
99.00 
98.42 
99.32 
99.41 
99.02 
97.02 
  
These values were evaluated on statistical tool graphpad instant. The 
calculated P ˂ 0.05 values were found to be 0.5316 which is greater than P value 
so consider to not significant. 
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Accuracy of HPTLC method: 
 
 The % RSD values of the HPTLC method are shown in table 49. 
                                        Table 49: % RSD of Accuracy  
Parameter % RSD 
 
 
HPTLC 
98.54 
99.02 
98.14 
97.54 
98.56 
98.75 
 
  
These values were evaluated on statistical tool graphpad instant. The calculated P 
˂ 0.05 values were found to be 0.0942 which is greater than P value so consider to 
not significant. 
  
The unpaired‘t’ test carried out for the precision that all the methods are 
equally precise. 
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Paired‘t’ test 
Comparison of accuracy of existing UV method with developed UV 
method. The % RSD values of the two methods shown in table 50. 
 
Table 50: % RSD of accuracy 
UV Existing UV 
99.00 100.10 
98.42 99.97 
99.32 98.27 
99.41 98.02 
99.02 99.91 
97.02 100.27 
 
These values were evaluated on statistical tool graphpad instant. The 
calculated P ˂ 0.05 values were found to be 0.2149 which is greater than P value 
so consider to not significant. 
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ANOVA 
 One way analysis of variance (ANOVA) test was applied on precision 
(intraday and interday precision) studies of the UV and HPTLC methods for 
Benfotiamine. 
Precision of assay:  
Intraday precision:  
 The % RSD values of three methods are shown in table 51. 
Table 51: % RSD of intraday precision 
UV HPTLC 
0.29 0.58 
0.47 1.27 
0.97 0.97 
0.84 0.74 
0.79 0.86 
0.68 0.69 
 
These values were evaluated on statistical tool graphpad instant. The 
calculated P ˂ 0.05 values were found to be 0.2207 which is greater than P value 
so consider to not significant. 
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Interday precision: 
 The % RSD values are shown in table 52. 
 
Table 52: % RSD of interday precision 
UV HPTLC 
0.09 0.38 
0.37 1.24 
0.98 0.91 
0.83 0.89 
1.72 0.68 
0.76 0.79 
  
The values were evaluated on statistical tool graphpad instant. The 
calculated P ˂ 0.05 values were found to be 0.2501 which is greater than P value 
so consider to not significant. 
 
Table 53: statistical comparison 
 
Parameter 
Intraday Interday 
Mean 
difference 
‘t’ 
value 
‘p’ 
value 
Mean 
difference 
‘t’ 
value 
‘p’ 
value 
UV Vs HPTLC 0.11 7.27 >0.05 0.018 6.54 >0.05 
  
 Statistical studies were carried out for HPLC and HPTLC method 
development of Benfotiamine in combination with Pyridoxamine dihydrochloride 
and Resveratrol. 
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Precision of assay for benfotiamine (intraday precision) 
 The % RSD values of the two methods are shown in table 54. 
 
Table 54: % RSD of intraday precision 
HPTLC HPLC 
0.58 0.16 
1.27 0.97 
0.92 1.97 
0.74 0.82 
0.86 0.78 
0.69 0.62 
 
 These values were evaluated on statistical tool graphpad instant. The 
calculated P ˂ 0.05 values were found to be 0.1697 which is greater than P value 
so consider to not significant. 
 
Precision of assay for benfotiamine (interday precision) 
 The % RSD values are shown in table 55. 
Table 55: % RSD of interday precision 
HPTLC HPLC 
0.38 0.06 
1.24 0.93 
0.91 1.12 
0.89 1.45 
0.68 0.76 
0.79 0.81 
 These values were evaluated on statistical tool graphpad instant. The 
calculated P ˂ 0.05 values were found to be 0.2945 which is greater than P value 
so consider to not significant. 
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Table 56: Statistical comparison 
Parameter 
Mean difference ‘t’ value ‘p’ 
value Intraday Interday Intraday Interday 
HPTLC Vs HPLC -0.0350 0.040 0.8476 0.7802 >0.05 
 
 
Precision of assay for Pyridoxamine dihydrochloride (intraday precision) 
The % RSD values of the two methods shown in table 57. 
Table 57:  % RSD of intraday precision 
HPTLC HPLC 
0.62 0.29 
0.64 0.57 
0.72 0.71 
1.02 0.82 
0.68 0.62 
0.47 0.47 
 
 These values were evaluated on statistical tool graphpad instant. The 
calculated P ˂ 0.05 values were found to be 0.2980 which is greater than P value 
so consider to not significant. 
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Precision of assay for Pyridoxamine dihydrochloride (interday precision) 
 The % RSD values are shown in table 58. 
 
Table 58: % RSD of interday precision 
HPTLC HPLC 
0.62 0.22 
1.44 1.09 
0.76 0.94 
0.51 0.82 
0.49 0.76 
0.91 0.54 
  
These values were evaluated on statistical tool graphpad instant. The 
calculated P ˂ 0.05 values were found to be 0.4245 which is greater than P value 
so consider to not significant. 
 
Table 59: Statistical comparison 
Parameter 
Mean difference ‘t’ value 
‘p’ value 
Intraday Interday Intraday Interday 
HPTLC Vs HPLC -0.036 0.060 0.8670 0.6888 >0.05 
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Precision of assay for Resveratrol (intraday precision) 
 The % RSD values of the two methods shown in table 60 
Table 60: % RSD of intraday precision 
HPTLC HPLC 
1.44 0.98 
1.94 0.94 
0.97 0.49 
0.25 1.21 
0.37 0.80 
0.72 0.79 
  
These values were evaluated on statistical tool graphpad instant. The 
calculated P ˂ 0.05 values were found to be 0.2763 which is greater than P value 
so consider to not significant. 
 
Precision of assay for Resveratrol (interday precision) 
 The % RSD values are shown in table 61 
Table 61: % RSD of interday precision 
HPTLC HPLC 
0.94 1.32 
1.32 1.24 
0.85 0.69 
0.71 0.35 
0.35 0.47 
0.55 0.78 
Results & Discussion 
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These values were evaluated on statistical tool graphpad instant. The 
calculated P ˂ 0.05 values were found to be 0.1950 which is greater than P value 
so consider to not significant. 
Table 62:  Statistical comparison 
Parameter 
Mean difference ‘t’ value ‘p’ value 
Intraday Interday Intraday Interday 
HPTLC Vs 
HPLC 
0.080 0.021 0.7934 0.8531 >0.05 
 
The paired‘t’ test carried out for the precision that all the methods are 
equally precise. 
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SUMMARY  
 In current research work newer analytical methods were developed and 
validated for benfotiamine in single dosage form and its combination with 
pyridoxamine dihydrochloride and resveratrol. An UV spectroscopy and stability 
indicating HPTLC methods were developed for the quantification of benfotiamine 
in single dosage form and for the estimation of benfotiamine in combined dosage 
form two chromatographic methods viz a HPTLC and HPLC were developed. 
Analytical methods for benfotiamine in single dosage form 
 The development of UV spectrophotometric method involved scanning of 
the standard and sample solutions in the UV range using UV visible 
spectrophotometer. Benfotiamine showed maximum absorbance at 240nm. The 
method was validated for linearity, precision, accuracy and stability. An overly of 
different concentrations of benfotiamine was noted with absorbance at λmax. The 
linear concentration was 4-24µg/ml and the correlation value was 0.999. The 
percentage RSD values of repeatability, interday and intraday were found to be 
˂ 2, which proves precision of the method. The drug solution was found to be 
stable up to 48hrs at room temperature. The method was the applied to estimation 
of Benfotiamine bulk drug and tablet formulation.  
For the estimation of Benfotiamine by HPTLC method, the sample 
solutions were applied on silica gel G60F254 TLC plates and the chromatogram was 
developed using mobile phase comprising of Glacial acetic acid : Methanol : 
Triethylamine ( 9: 1% v/v, 2drops) and detection was carried out at 275 nm using 
densitometer. The Rf value of Benfotiamine was 0.29±0.02, which showed 
linearity range from 0.1 – 0.6µg/spot and correlation coefficient 0.998. The 
percentage RSD values of repeatability, intraday and interday were found to be 
˂ 2. It proves precision of the method. 
Summary  
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 HPTLC method was applied for accelerated stability studies of 
Benfotiamine in bulk drug and tablet formulation for acid, alkali and oxidative 
degradation. The degradation study indicated benfotiamine is more susceptible to 
acid hydrolysis than other conditions. There were no additional peak observed 
when treated with all the degradation conditions, but reduction in peak area was 
found. The tablet placebo was prepared and subjected to degradation studies as 
like formulation, to know if any interferences due to this. It was observed that 
there was no additional peak at the Rf value of benfotiamine due to excipients. 
 The statistical analysis was applied to the assay results obtained by two 
newly developed methods (UV and HPTLC). The results of an unpaired’t’ test 
conducted is shown in table below.  
Parameter UV HPTLC 
Mean (assay) 98.63 98.42 
Number of points 6 6 
SD 0.982 0.520 
SEM 0.364 0.212 
Median 99.010 98.550 
P 0.5316 
F 2.937 
 For the statistical comparison of the developed UV method and existing 
UV method (13) for benfotiamine a paired ‘t’ test was conducted the results as 
shown in table below. 
Parameter UV UV 
Mean (assay) 98.69 99.42 
Number of points 6 6 
SD 0.892 1.001 
SEM 0.364 0.408 
Median 99.10 99.940 
P  0.2149 
F 1.258 
Summary  
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The results proved that there is no statistical significant difference among 
two developed methods for estimation of benfotiamine. 
One way ANOVA was carried out for the intraday and interday precision 
of UV and HPTLC method for benfotiamine estimation from tablets. The average 
mean difference was 0.11, t- value, 7.27 and p- value was >0.05 for intraday 
precision. For interday precision was mean difference 0.018, t- value 6.54 and p- 
value was>0.05. 
Analytical method for benfotiamine in combination with pyridoxamine 
dihydrochloride and resveratrol 
A newer HPTLC method was developed for estimation of benfotiamine in 
combination of pyridoxamine dihydrochloride and resveratrol combined dosage 
form. The sample solutions were applied TLC plates and the chromatogram was 
developed using mobile phase separation of Glacial acetic acid: petroleum ether: 
Acetone: Triethylamine: Tetra butyl ammonium bromide (5.5:1.5:3% v/v, 5drops, 
and 2drops) and detection was carried out a 285nm. The linearity range from 
benfotiamine 200-1200ng/spot, pyridoxamine dihydrochloride 100-600ng/spot 
and respectively for benfotiamine, pyridoxamine dihydrochloride and resveratrol. 
The method was successfully applied to the formulation containing these three 
drugs. 
A new high performance liquid chromatographic method was developed 
for determination of benfotiamine in combination with pyridoxamine 
dihydrochloride and resveratrol in tablet formulation. The chromatographic 
separation was performed on stationary phase of Lichrospher®100 RP – 18e 
(5µm) and mobile phase of 10mM KH2PO4 (pH- 4.9): Methanol + Acetonitrile 
and solvent ratio of 70: 15+15 %v/v, flow rate: 1.0ml/min. The detection 
wavelength was at 254nm. 
Summary  
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The method was validated for linearity, precision, stability and robustness. 
The linear concentration benfotiamine was 10-50µg/ml, pyridoxamine 
dihydrochloride 5-25µg/ml and resveratrol 5-25µg/ml. The correlation value was 
0.999, 0.997 and 0.999 respectively for benfotiamine, pyridoxamine 
dihydrochloride and resveratrol. The percentage RSD values of repeatability, 
interday and intraday precision were found to be ˂ 2. It proves precision of the 
method. The solution was stable up to 36 hours at room temperature. The method 
was robust for very minor change in the changed chromatographic parameters. 
A paired‘t’ test was conducted to test the precision of the two methods for 
every single drug present in combined dosage form. The results of paired t-test are 
benfotiamine in shown table below. 
Parameter 
HPTLC HPLC 
Intraday Interday Intraday Interday 
Mean (precision) 0.84 0.88 0.81 0.85 
Number of points 6 6 6 6 
SD 0.241 0.599 0.284 0.463 
SEM 0.098 0.244 0.116 0.189 
Median 0.800 0.800  0.368 
P 0.063 0.060 
T 0.2024 0.2945 
 
The statistical comparison of precision pyridoxamine dihydrochloride by 
paired ‘t’ test in shown table below.  
Parameter 
HPTLC HPLC 
Intraday Interday Intraday Interday 
Mean (precision) 0.69 0.58 0.78 0.72 
Number of points 6 6 6 6 
SD 0.182 0.185 0.356 0.309 
SEM 0.074 0.075 0.145 0.126 
Median 0.660 0.595 0.690 0.790 
P 0.08 0.17 
T 2.217 0.424 
Summary  
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The paired t-test results of resveratrol is shown table below. 
Parameter 
HPTLC HPLC 
Intraday Interday Intraday Interday 
Mean (precision) 0.94 0.86 0.78 0.80 
Number of points 6 6 6 6 
SD 0.648 0.240 0.336 0.396 
SEM 0.264 0.098 0.137 0.162 
Median 0.845 0.870 0.780 0.735 
P 0.793 0.853 
T 0.276 0.195 
 
 The results proved that there is no statistical significant difference among 
two and three developed methods for estimation of benfotiamine and it 
combination with pyridoxamine dihydrochloride and resveratrol. 
Conclusion 
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CONCLUSION 
 The UV, HPTLC and HPLC methods developed were validated as per ICH 
guidelines and found to be specific, accurate and precise. The results of all the 
methods were ascertained by statistical analysis. 
 Among the two analytical methods developed, HPTLC is more sensitive 
technique, whereas UV is a simpler technique for the estimation of Benfotiamine in 
single dosage form. The HPTLC is more sensitive than HPLC method for the 
analysis of Benfotiamine in combination with Pyridoxamine dihydrochloride and 
Resveratrol. However HPLC offers a more reliable quantification than HPTLC for 
combination. 
 All the four methods were successfully employed to analyse benfotiamine 
from single dosage form or in combination with Pyridoxamine dihydrochloride and 
Resveratrol. They would serve as good analytical tools for the quality control and 
research involving Benfotiamine and its combined dosage form with Pyridoxamine 
dihydrochloride and Resveratrol. 
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